



Royal College of  
Obstetricians and Gynaecologists

Bringing to life the best in women's health care

Green-top Guideline No. 31

2nd Edition | February 2013

Minor revisions – January 2014

# The Investigation and Management of the Small-for-Gestational-Age Fetus



# The Investigation and Management of the Small-for-Gestational-Age Fetus

This is the second edition of this guideline. It replaces the first edition which was published in November 2002 under the same title.

## Executive Summary of Recommendations

### *Risk factors for a SGA fetus/neonate*

All women should be assessed at booking for risk factors for a SGA fetus/neonate to identify those who require increased surveillance.



Women who have a major risk factor (Odds Ratio [OR] > 2.0) should be referred for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler from 26–28 weeks of pregnancy (Appendix 1).



Women who have three or more minor risk factors should be referred for uterine artery Doppler at 20–24 weeks of gestation (Appendix 1).



Second trimester DS markers have limited predictive accuracy for delivery of a SGA neonate.



A low level (< 0.415 MoM) of the first trimester marker PAPP-A should be considered a major risk factor for delivery of a SGA neonate.



In high risk populations uterine artery Doppler at 20–24 weeks of pregnancy has a moderate predictive value for a severely SGA neonate.



In women with an abnormal uterine artery Doppler at 20–24 weeks of pregnancy, subsequent normalisation of flow velocity indices is still associated with an increased risk of a SGA neonate. Repeating uterine artery Doppler is therefore of limited value.



Women with an abnormal uterine artery Doppler at 20–24 weeks (defined as a pulsatility index [PI] > 95<sup>th</sup> centile) and/or notching should be referred for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler commencing at 26–28 weeks of pregnancy.



Women with a normal uterine artery Doppler do not require serial measurement of fetal size and serial assessment of wellbeing with umbilical artery Doppler unless they develop specific pregnancy complications, for example antepartum haemorrhage or hypertension. However, they should be offered a scan for fetal size and umbilical artery Doppler during the third trimester.



Serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler should be offered in cases of fetal echogenic bowel.



Abdominal palpation has limited accuracy for the prediction of a SGA neonate and thus should not be routinely performed in this context.



Serial measurement of symphysis fundal height (SFH) is recommended at each antenatal appointment from 24 weeks of pregnancy as this improves prediction of a SGA neonate.



SFH should be plotted on a customised chart rather than a population-based chart as this may improve prediction of a SGA neonate.



Women with a single SFH which plots below the 10<sup>th</sup> centile or serial measurements which demonstrate slow or static growth by crossing centiles should be referred for ultrasound measurement of fetal size.



Women in whom measurement of SFH is inaccurate (for example: BMI > 35, large fibroids, hydramnios) should be referred for serial assessment of fetal size using ultrasound.



*Optimum method of diagnosing a SGA fetus and FGR*

Fetal abdominal circumference (AC) or estimated fetal weight (EFW) < 10<sup>th</sup> centile can be used to diagnose a SGA fetus.



Use of a customised fetal weight reference may improve prediction of a SGA neonate and adverse perinatal outcome. In women having serial assessment of fetal size, use of a customised fetal weight reference may improve the prediction of normal perinatal outcome.



Routine measurement of fetal AC or EFW in the third trimester does not reduce the incidence of a SGA neonate nor does it improve perinatal outcome. Routine fetal biometry is thus not justified.



Change in AC or EFW may improve the prediction of wasting at birth (neonatal morphometric indicators) and adverse perinatal outcome suggestive of FGR.



When using two measurements of AC or EFW to estimate growth velocity, they should be at least 3 weeks apart to minimise false-positive rates for diagnosing FGR. More frequent measurements of fetal size may be appropriate where birth weight prediction is relevant outside of the context of diagnosing SGA/FGR.



Where the fetal AC or EFW is < 10<sup>th</sup> centile or there is evidence of reduced growth velocity, women should be offered serial assessment of fetal size and umbilical artery Doppler.



*Investigations that are indicated in SGA fetuses*

Offer referral for a detailed fetal anatomical survey and uterine artery Doppler by a fetal medicine specialist if severe SGA is identified at the 18–20 week scan.



Karyotyping should be offered in severely SGA fetuses with structural anomalies and in those detected before 23 weeks of gestation, especially if uterine artery Doppler is normal.



Serological screening for congenital cytomegalovirus (CMV) and toxoplasmosis infection should be offered in severely SGA fetuses.



Testing for syphilis and malaria should be considered in high risk populations.



Uterine artery Doppler has limited accuracy to predict adverse outcome in SGA fetuses diagnosed during the third trimester.



*Interventions to be considered in the prevention of SGA fetuses/neonates*

Antiplatelet agents may be effective in preventing SGA birth in women at high risk of pre-eclampsia although the effect size is small.

C

In women at high risk of pre-eclampsia, antiplatelet agents should be commenced at, or before, 16 weeks of pregnancy.

A

There is no consistent evidence that dietary modification, progesterone or calcium prevent birth of a SGA infant. These interventions should not be used for this indication.

A

Interventions to promote smoking cessation may prevent delivery of a SGA infant. The health benefits of smoking cessation indicate that these interventions should be offered to all women who are pregnant and smoke.

A

Antithrombotic therapy appears to be a promising therapy for preventing delivery of a SGA infant in high-risk women. However there is insufficient evidence, especially concerning serious adverse effects, to recommend its use.

D

*Interventions to be considered in the preterm SGA fetus*

Women with a SGA fetus between 24<sup>+0</sup> and 35<sup>+6</sup> weeks of gestation, where delivery is being considered, should receive a single course of antenatal corticosteroids.

C

*Optimal method and frequency of fetal surveillance in SGA*

In a high-risk population, the use of umbilical artery Doppler has been shown to reduce perinatal morbidity and mortality. Umbilical artery Doppler should be the primary surveillance tool in the SGA fetus.

A

When umbilical artery Doppler flow indices are normal it is reasonable to repeat surveillance every 14 days.

B

More frequent Doppler surveillance may be appropriate in a severely SGA fetus.

✓

When umbilical artery Doppler flow indices are abnormal (pulsatility or resistance index > +2 SDs above mean for gestational age) and delivery is not indicated repeat surveillance twice weekly in fetuses with end-diastolic velocities present and daily in fetuses with absent/reversed end-diastolic frequencies.

✓

CTG should not be used as the only form of surveillance in SGA fetuses.

A

Interpretation of the CTG should be based on short term fetal heart rate variation from computerised analysis.

A

Ultrasound assessment of amniotic fluid volume should not be used as the only form of surveillance in SGA fetuses.

✓

Interpretation of amniotic fluid volume should be based on single deepest vertical pocket.

A

Biophysical profile should not be used for fetal surveillance in preterm SGA fetuses.

A

In the preterm SGA fetus, middle cerebral artery (MCA) Doppler has limited accuracy to predict acidaemia and adverse outcome and should not be used to time delivery.

B

In the term SGA fetus with normal umbilical artery Doppler, an abnormal middle cerebral artery Doppler (PI < 5<sup>th</sup> centile) has moderate predictive value for acidosis at birth and should be used to time delivery.

C

Ductus venosus Doppler has moderate predictive value for acidaemia and adverse outcome.

A

Ductus venosus Doppler should be used for surveillance in the preterm SGA fetus with abnormal umbilical artery Doppler and used to time delivery.

✓

### *The optimal gestation to deliver the SGA fetus*

In the preterm SGA fetus with umbilical artery AREDV detected prior to 32 weeks of gestation, delivery is recommended when DV Doppler becomes abnormal or UV pulsations appear, provided the fetus is considered viable and after completion of steroids. Even when venous Doppler is normal, delivery is recommended by 32 weeks of gestation and should be considered between 30–32 weeks of gestation.

✓

If MCA Doppler is abnormal, delivery should be recommended no later than 37 weeks of gestation.

C

In the SGA fetus detected after 32 weeks of gestation with an abnormal umbilical artery Doppler, delivery no later than 37 weeks of gestation is recommended.

✓

In the SGA fetus detected after 32 weeks of gestation with normal umbilical artery Doppler, a senior obstetrician should be involved in determining the timing and mode of birth of these pregnancies. Delivery should be offered at 37 weeks of gestation.

A

### *How the SGA fetus should be delivered*

In the SGA fetus with umbilical artery AREDV delivery by caesarean section is recommended.

✓

In the SGA fetus with normal umbilical artery Doppler or with abnormal umbilical artery PI but end-diastolic velocities present, induction of labour can be offered but rates of emergency caesarean section are increased and continuous fetal heart rate monitoring is recommended from the onset of uterine contractions.

B

Early admission is recommended in women in spontaneous labour with a SGA fetus in order to instigate continuous fetal heart rate monitoring.

✓

## 1. Purpose and scope

The purpose of this guideline is to provide advice that is based on the best evidence where available in order to guide clinicians, regarding the investigation and management of the small-for-gestational age (SGA) fetus. The guideline reviews the risk factors for a SGA fetus and provides recommendations regarding screening, diagnosis and management, including fetal monitoring and delivery.

### *1.1 Population and setting*

Unselected pregnant women in community settings.

High-risk women (calculated on the basis of past obstetric history, current medical disorders or ultrasound diagnosis) in the hospital setting.

The guideline does not address multiple pregnancies or pregnancies with fetal abnormalities.

## 1.2. Interventions to be studied

Comparison of modalities to screen for and diagnose a SGA fetus.

Comparison of modalities to monitor a SGA fetus.

## 2. Definitions

Small-for-gestational age (SGA) refers to an infant born with a birth weight less than the 10<sup>th</sup> centile. Historically SGA birth has been defined using population centiles. But, the use of centiles customised for maternal characteristics (maternal height, weight, parity and ethnic group) as well as gestational age at delivery and infant sex, identifies small babies at higher risk of morbidity and mortality than those identified by population centiles.<sup>1-2</sup> With respect to the fetus, definitions of SGA birth and severe SGA vary. For the purposes of this guideline, SGA birth is defined as an estimated fetal weight (EFW) or abdominal circumference (AC) less than the 10<sup>th</sup> centile and severe SGA as an EFW or AC less than the 3<sup>rd</sup> centile.<sup>3</sup> Other definitions will be discussed where relevant.

Fetal growth restriction (FGR) is not synonymous with SGA. Some, but not all, growth restricted fetuses/infants are SGA while 50–70% of SGA fetuses are constitutionally small, with fetal growth appropriate for maternal size and ethnicity.<sup>4</sup> The likelihood of FGR is higher in severe SGA infants. Growth restriction implies a pathological restriction of the genetic growth potential. As a result, growth restricted fetuses may manifest evidence of fetal compromise (abnormal Doppler studies, reduced liquor volume). Low birth weight (LBW) refers to an infant with a birth weight < 2500 g.

As some of the definitions used in the published literature vary, or as in the case of FGR, can be used inappropriately, further clarification is given where necessary throughout the guideline when referring to the evidence.

## 3. Background

Small fetuses are divided into normal (constitutionally) small, non-placenta mediated growth restriction, for example; structural or chromosomal anomaly, inborn errors of metabolism and fetal infection, and placenta mediated growth restriction. Maternal factors can affect placental transfer of nutrients, for example; low pre-pregnancy weight, under nutrition, substance abuse or severe anaemia. Medical conditions can affect placental implantation and vasculature and hence transfer, for example; pre-eclampsia, autoimmune disease, thrombophilias, renal disease, diabetes and essential hypertension.

As a group, structurally normal SGA fetuses are at increased risk of perinatal mortality and morbidity but most adverse outcomes are concentrated in the growth restricted group. Several studies have shown that neonates defined as SGA by population-based birthweight centiles but not customised centiles are not at increased risk of perinatal morbidity or mortality.<sup>1,2,5</sup>

Clinical examination is a method of screening for fetal size, but is unreliable in detecting SGA fetuses. Diagnosis of a SGA fetus usually relies on ultrasound measurement of fetal abdominal circumference or estimation of fetal weight. Management of the SGA fetus is directed at timely delivery. A number of surveillance tests are available, including cardiotocography, Doppler and ultrasound to assess biophysical activity but there is controversy about which test or combination of tests should be used to time delivery, especially in the fetus.

## 4. Identification and assessment of evidence

This guideline was developed in accordance with standard methodology for producing RCOG Green-top Guidelines. Medline, Pubmed, all EBM reviews (Cochrane CRCT, Cochrane database of Systematic Reviews,

methodology register, ACP journal club, DARE HTA, Maternity and Infant Care), EMBASE and TRIP were searched for relevant randomised controlled trials (RCTs), systematic reviews, meta-analyses and cohort studies. The search was restricted to articles published between 2002 and September 2011. Search words included 'fetal growth retardation', 'fetal growth restriction', 'infant, small for gestational age', including all relevant Medical Subject Heading (MeSH) terms. The search was limited to humans and the English language.

## 5. What are the risk factors for a SGA fetus/neonate? What is the optimum method of screening for the SGA fetus/neonate and care of "at risk" pregnancies?

Methods employed in the first and second trimesters, to predict the likelihood of a SGA fetus/neonate include: medical and obstetric history and examination, maternal serum screening and uterine artery Doppler. Methods of screening for the SGA fetus/neonate in the second and third trimester are abdominal palpation and measurement of symphysis fundal height (SFH) (including customised charts).

### 5.1 History

**All women should be assessed at booking for risk factors for a SGA fetus/neonate to identify those who require increased surveillance.**



**Women who have a major risk factor (Odds Ratio [OR] > 2.0) should be referred for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler from 26–28 weeks of pregnancy (Appendix 1).**



**Women who have three or more minor risk factors should be referred for uterine artery Doppler at 20–24 weeks of gestation (Appendix 1).**



A table of risk factors and associated odds ratios (ORs) for the birth of a SGA neonate, where evidence is consistent and not affected by adjustment for confounders, is presented in Appendix 1. It is acknowledged that other risk factors may need to be considered on an individual basis.

Women that have previously had a SGA neonate have at least a twofold increased risk of a subsequent SGA neonate.<sup>6-8</sup> The risk is increased further after two SGA births.<sup>7</sup> Classification of prior infant birthweight is best done using customised centiles.<sup>1-2</sup> This can be done using computer software that can be downloaded from the internet.<sup>9</sup> Women with a prior history of other placenta-mediated diseases are also at increased risk of a subsequent SGA neonate. This includes prior pre-eclampsia<sup>8</sup> and prior stillbirth,<sup>7</sup> and in particular those with a history of previous preterm unexplained stillbirth, due to the association with FGR.<sup>10</sup> While termination of pregnancy is not a risk factor for a SGA infant,<sup>11</sup> the evidence regarding recurrent miscarriage is inconsistent.<sup>12,13</sup>

Maternal medical conditions associated with an increased risk of a SGA neonate are diabetes with vascular disease,<sup>14</sup> moderate and severe renal impairment (especially when associated with hypertension),<sup>15</sup> antiphospholipid syndrome<sup>16</sup> and chronic hypertension.<sup>17</sup> Systemic lupus erythematosus<sup>18</sup> and certain types of congenital heart disease, in particular cyanotic congenital heart disease, are associated with increased likelihood of a SGA neonate but there are no papers reporting ORs.<sup>19</sup> The risk will therefore need to be assessed on an individual basis. The evidence for an association with asthma, thyroid disease, inflammatory bowel disease and depression is less convincing. Studies report a weak or non-significant association with LBW but do not differentiate between the effect on SGA and preterm birth, and with confidence intervals [CIs] often crossing one. Therefore, if uncomplicated and adequately treated, these are not considered to be risk factors for a SGA fetus.<sup>20,21</sup>

Maternal risk factors associated with an increased risk of a SGA neonate are maternal age  $\geq 35$  years, with a further increase in those  $\geq 40$  years old,<sup>22</sup> African American<sup>23</sup> or Indian/Asian ethnicity,<sup>2,24</sup> nulliparity,<sup>25</sup> social deprivation,<sup>26</sup> unmarried status,<sup>27</sup> body mass index (BMI)  $< 20$ ,<sup>28-30</sup> BMI  $> 25$ ,<sup>28,29</sup> maternal SGA,<sup>31</sup> daily vigorous

exercise,<sup>32</sup> a short (< 6 months) or long (> 60 months) inter-pregnancy interval<sup>33</sup> and heavy vaginal bleeding during the first trimester.<sup>34</sup> The effect of some of these risk factors is reduced once adjusted for other associated factors and thus they are not included in Appendix 1. Maternal exposure to domestic violence during pregnancy has been shown in a systematic review to be associated with low birth weight (Adjusted OR [AOR] 1.53, 95% CI 1.28–1.82).<sup>35</sup> Low maternal weight gain has been shown to be associated with a SGA infant in a preterm population (OR 4.9, 95% CI 1.9–12.6)<sup>15</sup> but it is no longer recommended that women are routinely weighed during pregnancy.<sup>36</sup>

Several maternal exposures have a seemingly causative relationship with a SGA infant, including moderate alcohol intake,<sup>37</sup> drug use (with cocaine use during pregnancy being the most significant)<sup>38</sup> and cigarette smoking.<sup>39</sup> The effects of smoking are dose dependent.<sup>29</sup>

Other risk factors are maternal caffeine consumption  $\geq$  300 mg per day in the third trimester<sup>40</sup> and a low fruit intake pre-pregnancy, while a high green leafy vegetable intake pre-pregnancy has been reported to be protective (AOR 0.44, 95% CI 0.24–0.81).<sup>32</sup> Singleton pregnancies following IVF are also a risk factor for a SGA fetus.<sup>41</sup>

Changing paternity has been associated with an increased risk of a SGA infant,<sup>42</sup> although a recent systematic review demonstrated inconclusive evidence.<sup>43</sup> A paternal history of SGA birth is a risk factor for a SGA fetus.<sup>44</sup>

Evidence level 3

There is insufficient evidence to determine how risk factors relate to each other in the individual woman and consequently how these risk factors should be managed. This includes abnormal maternal Down syndrome serum markers (see below). Further evidence may become available from the SCOPE study.<sup>45</sup> This guideline has therefore categorized risk factors into major and minor based on published ORs for the birth of a SGA neonate. Major risk factors (OR > 2.0) should prompt referral for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler. The presence of multiple minor risk factors is likely to constitute a significant risk for the birth of a SGA neonate and there is a rationale for further screening using uterine artery Doppler at 20 weeks (see below).

## 5.2 Biochemical markers used for Down Syndrome (DS) Screening

**Second trimester DS markers have limited predictive accuracy for delivery of a SGA neonate.**

B

**A low level (< 0.415 MoM) of the first trimester marker PAPP-A should be considered a major risk factor for delivery of a SGA neonate.**

✓

Due to their placental origin, several biochemical markers have been investigated as screening tests for a SGA fetus.

Two systematic reviews found low predictive accuracy for alpha fetoprotein (AFP) (> 2.5 MoM or < 0.25 MoM), elevated hCG (> 3.0 MoM) and inhibin A ( $\geq$  2.0 MoM), low unconjugated estriol (< 0.5 MoM) and the combined triple test to predict a SGA fetus.<sup>46,47</sup> One review found methodological and reporting limitations in all studies, resulting in great heterogeneity, concluding that serum markers were only useful as a means of contributing to the overall assessment of risk for a pregnancy.<sup>47</sup>

Evidence level 1+/2+

In women with elevated AFP, there is no evidence that increased fetal surveillance has any benefit.<sup>48</sup> Similarly, there is a lack of evidence for the use of aspirin in women with raised hCG.<sup>49</sup>

Evidence level 3

In a large series of 49801 women at 11<sup>+</sup>0 to 13<sup>+</sup>6 weeks, low PAPP-A (but not beta HCG) was inversely associated with risk of being SGA. Using a 5<sup>th</sup> centile (0.415 MoM) cut off, ORs for a SGA infant (birthweight < 10<sup>th</sup> centile) and severe SGA (birthweight < 3<sup>rd</sup> centile) were 2.7 and 3.66 respectively.<sup>50</sup> A systematic review



found that an unexplained low first trimester PAPP-A (< 0.4 MoM) and/or a low hCG (< 0.5 MoM) were associated with an increased frequency of adverse obstetrical outcome including a SGA infant.<sup>47</sup>

There is some evidence that addition of fetal size at 18–20 weeks of gestation or fetal growth between 11–14 and 18–20 weeks of gestation to first trimester serum markers improves prediction of a SGA infant.<sup>51,52</sup> However, different ultrasound parameters have been used and it is unclear what combination provides optimum prediction.

Evidence level 2+

### 5.3 Uterine artery Doppler

**In high risk populations uterine artery Doppler at 20–24 weeks of pregnancy has a moderate predictive value for a severely SGA neonate.**

A

**In women with an abnormal uterine artery Doppler at 20–24 weeks of pregnancy, subsequent normalisation of flow velocity indices is still associated with an increased risk of a SGA neonate. Repeating uterine artery Doppler is therefore of limited value.**

C

**Women with an abnormal uterine artery Doppler at 20–24 weeks (defined as a pulsatility index [PI] > 95<sup>th</sup> centile) and/or notching should be referred for serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler commencing at 26–28 weeks of pregnancy.**

✓

**Women with a normal uterine artery Doppler do not require serial measurement of fetal size and serial assessment of wellbeing with umbilical artery Doppler unless they develop specific pregnancy complications, for example antepartum haemorrhage or hypertension. However, they should be offered a scan for fetal size and umbilical artery Doppler during the third trimester.**

✓

SGA birth, particularly when severe (birth weight < 3<sup>rd</sup> centile) or necessitating delivery < 36 weeks of gestation, is characterised by failure of trophoblast invasion of the myometrial uterine spiral arteries and reduced uteroplacental blood flow. Non-pregnant and first trimester artery blood flow velocity waveforms are associated with low end-diastolic velocities and an early diastolic notch. Persistent notching or abnormal flow velocity ratios after 24 weeks of gestation are associated with inadequate trophoblast invasion of the myometrial spiral arteries.<sup>53</sup> However reduced endovascular trophoblast invasion of decidual spiral arteries has been associated with the same waveform abnormalities as early as 10–14 weeks of pregnancy.<sup>54</sup>

A systematic review and meta-analysis summarised the results from 61 studies testing 41 131 pregnant women with uterine artery Doppler (in both first and second trimesters) and assessed the value of different Doppler flow velocity indices.<sup>55</sup> SGA birth in low risk patients was best predicted by an increased pulsatility index (PI) (defined as > 95<sup>th</sup> centile) with diastolic notching (positive likelihood ratio [LR+] 9.1, 95% CI 5.0–16.7; negative likelihood ratio [LR-] 0.89, 95% CI 0.85–0.93). Severe SGA (birthweight < 5<sup>th</sup> or < 3<sup>rd</sup> centile) in low risk populations was best predicted in the second trimester by an increased PI (LR+ 13.7, 95% CI 10.3–16.9; LR- 0.34, 95% CI 0.23–0.48) or an increased PI with notching (LR+ 14.6, 95% CI 7.8–26.3; LR- 0.78, 95% CI 0.68–0.87). Uterine artery Doppler to predict a SGA infant in high risk populations overall showed low predictive characteristics; an increased PI or notching in the second trimester best predicted a SGA infant (LR+ 3.6, 95% CI 2.0–5.1; LR- 0.40, 95% CI 0.14–0.65). Prediction of severe SGA showed moderate utility with the best prediction by a resistance index (> 0.58 or > 90<sup>th</sup> centile) and notching in the second trimester (LR+ 10.9, 95% CI 10.4–11.4; LR- 0.20, 95% CI 0.14–0.26). Although first trimester uterine artery Doppler studies suggest a high specificity (91–96%) and high negative predictive values (91–99%), the low sensitivity (12–25%) for a SGA neonate suggest early screening cannot be recommended on current evidence.<sup>55</sup>

There were three studies included in this review that looked at prediction of early onset SGA, all of which were in low risk/unselected populations.<sup>55</sup> Increased PI in the second trimester has been shown to be predictive of delivery of a SGA fetus < 34 weeks in two studies (LR+ 13.7, 95% CI

Evidence level 1

11.3–16.7; LR- 0.37, 95% CI 0.27–0.52) and < 32 weeks in one study (LR+ 14.6, 95% CI 11.5–18.7; LR- 0.31 0.18–0.53).

Evidence  
level 1

In approximately 60% of cases with abnormal uterine artery Doppler at 20–22 weeks of gestation, PI remains increased at 26–28 weeks.<sup>56</sup> This group had the highest risk of a SGA infant (32%) compared to control women with normal Doppler at 20–22 weeks of gestation (1%). However, even when uterine artery PI normalised by 26–28 weeks of gestation, the incidence of a SGA infant was higher than in controls (9.5%). Thus at present the evidence suggests that repeating uterine artery Doppler later in the second trimester appears to be of limited value.

A systematic review assessing the effects on pregnancy outcome of routine utero-placental Doppler ultrasound in the second trimester showed no benefit to mother or baby. However this review included only two studies involving 4993 participants and women were all low risk for hypertensive disorders.<sup>57</sup>

Evidence  
level 1++

The combination of uterine artery Doppler and maternal serum markers has been shown in case-control and cohort studies to have an improved predictive ability for the SGA neonate, although predictive values are still poor.<sup>58–60</sup> Use of combination testing in the second trimester appears to predict adverse outcome related to placental insufficiency more effectively than first trimester screening.<sup>61</sup>

Evidence  
level 2+

The developers' interpretation of the evidence relating to uterine artery Doppler screening is that the LR- is insufficient to negate the risk associated with a major risk factor for a SGA neonate. In these women we would not recommend uterine artery Doppler, as it would not change care. They should be offered serial assessment of fetal size and umbilical artery Doppler from 26–28 weeks of pregnancy. For women with multiple minor risk factors, the developers consider there to be value in uterine artery Doppler screening at 20–24 weeks of pregnancy, with the institution of serial assessment of fetal size and umbilical artery Doppler from 26–28 weeks of pregnancy in those with an abnormal result, given the LR+. In those with a normal result there may still be value in a single assessment of fetal size and umbilical artery Doppler during the third trimester.

#### 5.4 Fetal echogenic bowel

**Serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler should be offered in cases of fetal echogenic bowel.**

C

Fetal echogenic bowel has been shown to be independently associated with a SGA neonate (AOR 2.1, 95% CI 1.5–2.9) and fetal demise (AOR 9.6, 95% CI 5.8–15.9).<sup>62</sup> Serial measurements of fetal size and umbilical artery Doppler is indicated following confirmation of echogenic bowel.

An algorithm to assist in the screening of the SGA fetus is provided in Appendix 2. Risk should be assessed at booking and then reassessed at 20–24 weeks in the light of additional pregnancy screening information, for example; Down syndrome markers, 18–20 week fetal anomaly scan. Several pregnancy complications (pre-eclampsia,<sup>7,17</sup> pregnancy-induced hypertension,<sup>17</sup> unexplained antepartum haemorrhage<sup>46</sup> and abruption<sup>63</sup>) increase the risk of a SGA neonate and are indications for serial assessment of fetal size and umbilical artery Doppler.

#### 5.5 Clinical examination

**Abdominal palpation has limited accuracy for the prediction of a SGA neonate and thus should not be routinely performed in this context.**

C

**Serial measurement of symphysis fundal height (SFH) is recommended at each antenatal appointment from 24 weeks of pregnancy as this improves prediction of a SGA neonate.**

B

**SFH should be plotted on a customised chart rather than a population-based chart as this may improve prediction of a SGA neonate.**

✓

**Women with a single SFH which plots below the 10<sup>th</sup> centile or serial measurements which demonstrate slow or static growth by crossing centiles should be referred for ultrasound measurement of fetal size.**



**Women in whom measurement of SFH is inaccurate (for example: BMI > 35, large fibroids, hydramnios) should be referred for serial assessment of fetal size using ultrasound.**



Cohort and case-control studies performed in low risk populations have consistently shown abdominal palpation to be of limited accuracy in the detection of a SGA neonate (sensitivity 19–21%, specificity 98%) and severely SGA neonate (< 2.3<sup>rd</sup> centile, sensitivity 28%).<sup>65,66</sup> In mixed risk populations, the sensitivity increases to 32–44%.<sup>67,68</sup> In high risk populations sensitivity is reported as 37% for a SGA neonate and 53% for severe SGA.<sup>65</sup>

Evidence level 2+

SFH should be measured from the fundus (variable point) to the symphysis pubis (fixed point) with the cm values hidden from the examiner.<sup>68</sup> Measurements should be plotted on a customised centile chart (see below). Women with a single SFH which plots below the 10<sup>th</sup> centile or serial measurements which demonstrate slow or static growth (i.e. they cross centiles in a downward direction) should be referred for further investigation (Appendix 3). There is no evidence to determine the number of centiles to be crossed to prompt referral.

A recent systematic review of five studies highlighted the wide variation of predictive accuracy of SFH measurement for a SGA infant.<sup>69</sup> Although early studies reported sensitivities of 56–86% and specificities of 80–93% for SFH detection of a SGA neonate,<sup>70–72</sup> a large study of 2941 women reported SFH to be less predictive with a sensitivity of 27% and specificity of 88% (LR+ 2.22, 95% CI 1.77–2.78; LR- 0.83, 95% CI 0.77–0.90).<sup>73</sup> Maternal obesity, abnormal fetal lie, large fibroids, hydramnios and fetal head engagement contribute to the limited predictive accuracy of SFH measurement. SFH is associated with significant intra- and inter-observer variation<sup>69,74</sup> and serial measurement may improve predictive accuracy.<sup>75</sup>

Evidence level 2++

The impact on perinatal outcome of measuring SFH is uncertain. A systematic review found only one trial with 1639 women which showed that SFH measurement did not improve any of the perinatal outcomes measured.<sup>76</sup>

A customised SFH chart is adjusted for maternal characteristics (maternal height, weight, parity and ethnic group). Calculation of customised centiles requires computer software that can be downloaded from the Internet.<sup>9</sup>

No trials were identified that compared customised with non-customised SFH charts and thus evidence for their effectiveness on outcomes such as perinatal morbidity/mortality is lacking. However observational studies suggest that customised SFH charts may improve the detection of a SGA neonate. In one study, use of customised charts, with referral when a single SFH measurement fell below the 10<sup>th</sup> centile or the last two measurements were above 10<sup>th</sup> centile but the slope was flatter than the 10<sup>th</sup> centile line, resulted in improved sensitivity for a SGA neonate (48% versus 29%, OR 2.2, 95% CI 1.1–4.5) compared to abdominal palpation.<sup>77</sup> Use of customised charts was also associated with fewer referrals for investigation and fewer admissions. An audit from the West Midlands also showed that use of customised SFH charts detected 36% of SGA neonates compared with only 16% when customised charts were not used.<sup>78</sup>

Evidence level 3

## 6. What is the optimum method of diagnosing a SGA fetus and FGR?

**Fetal abdominal circumference (AC) or estimated fetal weight (EFW) < 10<sup>th</sup> centile can be used to diagnose a SGA fetus.**



Use of a customised fetal weight reference may improve prediction of a SGA neonate and adverse perinatal outcome. In women having serial assessment of fetal size, use of a customised fetal weight reference may improve the prediction of normal perinatal outcome.

C

Routine measurement of fetal AC or EFW in the third trimester does not reduce the incidence of a SGA neonate nor does it improve perinatal outcome. Routine fetal biometry is thus not justified.

A

Change in AC or EFW may improve the prediction of wasting at birth (neonatal morphometric indicators) and adverse perinatal outcome suggestive of FGR.

C

When using two measurements of AC or EFW to estimate growth velocity, they should be at least 3 weeks apart to minimise false-positive rates for diagnosing FGR. More frequent measurements of fetal size may be appropriate where birth weight prediction is relevant outside of the context of diagnosing SGA/FGR.

C

Where the fetal AC or EFW is < 10<sup>th</sup> centile or there is evidence of reduced growth velocity, women should be offered serial assessment of fetal size and umbilical artery Doppler (see Section 7).

✓

### 6.1 Ultrasound biometry

Two systematic reviews have assessed the accuracy of ultrasound biometric measures, both as individual measures, as ratios, and combined (as the EFW).<sup>3,79</sup> Use of the 10<sup>th</sup> centile had better sensitivities and specificities than other commonly used centiles.<sup>66</sup> In a low risk population sensitivity varies from 0–10% and specificity 66–99% for any parameter. In a high risk population, fetal AC < 10<sup>th</sup> centile had sensitivity ranging from 72.9–94.5% and specificity 50.6–83.8%. For EFW < 10<sup>th</sup> centile, sensitivity was 33.3–89.2% and specificity 53.7–90.9%.<sup>3,79</sup> Meta-analysis was not performed in these systematic reviews due to the considerable clinical and methodological heterogeneity within the included papers. The potential advantage of EFW is that customised standards exist and accuracy can more easily be determined against birthweight.

A retrospective study has shown that among high risk patients, EFW and AC < 10<sup>th</sup> centile within 21 days of delivery better predicted a SGA infant than AC < 10<sup>th</sup> centile (80% versus 49%, OR 4.26, 95% CI 1.94–9.16).<sup>80</sup> Adverse perinatal outcome was also highest when both measures were < 10<sup>th</sup> centile.<sup>80</sup> Kayem et al.<sup>81</sup> found that measurement of AC in low risk women at term was a better predictor of birth weight ≤ 2.5 kg than a single measurement of SFH (LR+ 9.9 versus 7.1, LR- 0.5 versus 0.6).

Evidence level 2++

Several studies have compared various formulae for estimating fetal weight in unselected patients. A prospective study compared 35 different formulae and found that most are relatively accurate at predicting birth weight up to 3500 g.<sup>82</sup> Another study found the Shepard and Aoki formulae to have the best intraclass correlation coefficient, with EFW showing the smallest mean difference from actual birth weight.<sup>83</sup> Although formulae have been developed for SGA fetuses, there is little evidence that accurate prediction of weight is substantially improved<sup>84,85</sup> and in this population the Hadlock formula<sup>86</sup> may be most appropriate to use.

Evidence level 2-

There is no evidence to recommend one specific method of measuring AC (directly or derived from abdominal diameters) nor which centile chart to use. The centile charts produced by Chitty et al.<sup>87</sup> were optimally constructed and are widely used.

The same maternal characteristics (maternal height, weight, parity and ethnic group) that affect birth weight affect fetal biometric measures and fetal weight gain,<sup>88,89</sup> providing a rationale for the use of a customised AC or EFW chart.<sup>9</sup> A customised EFW < 10<sup>th</sup> centile is predictive of a SGA neonate (sensitivity 68%, specificity 89%).<sup>90</sup> Use of customised fetal weight centiles to define SGA

Evidence level 3

has also been shown to improve the prediction of adverse prenatal outcome;<sup>90,91</sup> OR of adverse outcomes (stillbirths, neonatal deaths, referral to higher level or special care unit or Apgar score < 7 at 5 minutes) for SGA neonates versus those not SGA was 1.59 (95% CI 1.53-1.66) for the non-customised fetal weight reference compared with 2.84 (95% CI 2.71-2.99) for the customised reference.<sup>90</sup> Prediction of perinatal mortality was also improved by the customised reference (OR 3.65, 95% CI 3.40-3.92 versus OR 1.77, 95% CI 1.65-1.89).<sup>91</sup> A further study demonstrated that individual growth trajectories of low risk fetuses with normal outcome were less likely to cross below the 10<sup>th</sup> centile for fetal weight when using customised reference standards than when unadjusted standards were used.<sup>92</sup> However, no trials were identified that compared customised with non-customised EFW charts.

Evidence  
level 3

A meta-analysis, including eight trials comprising 27 024 women, found no evidence that routine fetal biometry (with or without assessment of amniotic fluid volume and placental grade) after 24 weeks of pregnancy improved perinatal outcome in a low risk population (SGA neonate relative risk [RR] 0.98, 95% CI 0.74-1.28; perinatal mortality RR 0.94, 95% CI 0.55-1.61).<sup>93</sup> The timing and content of the ultrasound scan varied substantially between studies and the authors noted high heterogeneity between studies in the reduction of the risk of a SGA neonate, mainly due to the findings of one study in which routine estimation of fetal weight, amniotic fluid volume and placental grading at 30-32 and 36-37 weeks of gestation was shown to result in the birth of fewer SGA neonates (10.4% versus 6.9%, RR 0.67, 95% CI 0.50-0.89).<sup>94</sup>

Evidence  
level 1+

The change in fetal size between two time points is a direct measure of fetal growth and hence serial measurement of AC or EFW (growth velocities) should allow the diagnosis of FGR. However the optimal method of using serial ultrasound measurements is not clear. Although 'eyeballing' a chart of individual AC or EFW measurements may give an impression of FGR a more objective definition requires establishment of growth rate standards from longitudinally collected data. Several standards have been reported,<sup>95,96</sup> including conditional centiles for fetal growth,<sup>97</sup> although none has been adopted in clinical practice. Reported mean growth rates for AC and EFW after 30 weeks of gestation are 10 mm/14 days and 200 g/14 days although greater variation exists in the lower limits (reflecting the methods used to derive the standard deviation [SD]).<sup>98</sup> However a change in AC of < 5mm over 14 days is suggestive of FGR.<sup>95</sup> In a high risk population, identified as being SGA, Chang et al.<sup>99,100</sup> showed that a change in AC or EFW (defined as a change in SD score of  $\geq -1.5$ ) were better predictors of wasting at birth (ponderal index, mid-arm circumference/head circumference ratio or subscapular skinfold thickness < 2 SD below mean) and adverse perinatal outcome than the final AC or EFW before delivery.

Evidence  
level 2+

Mongelli et al.<sup>101</sup> used a mathematical model to estimate the impact of time interval between examinations on the false positive rates for FGR (defined as no apparent growth in fetal AC between two consecutive examinations). When the initial scan was performed at 32 weeks of gestation, the false positive rates were 30.8%, 16.9%, 8.1% and 3.2% for intervals of 1, 2, 3 and 4 weeks respectively. False positive rates were higher when the first scan was performed at 36 weeks of gestation (34.4%, 22.1%, 12.7%, 6.9% respectively). These findings suggest that if two measurements are to be used to estimate velocity, they should be a minimum of 3 weeks apart to minimise false-positive rates for diagnosing FGR. This recommendation does not preclude more frequent ultrasound measurements of AC/EFW to predict fetal size at birth but rather indicates which measurements should be used to interpret growth.

Evidence  
level 3

## 6.2 Biophysical tests

Biophysical tests, including amniotic fluid volume, cardiotocography (CTG) and biophysical scoring are poor at diagnosing a small or growth restricted fetus.<sup>102-104</sup> A systematic review of the accuracy of umbilical artery

Doppler in a high-risk population to diagnose a SGA neonate has shown moderate accuracy (LR+ 3.76, 95% CI 2.96–4.76; LR- 0.52, 95% CI 0.45–0.61).<sup>105</sup>

## 7. What investigations are indicated in SGA fetuses?

Offer a referral for a detailed fetal anatomical survey and uterine artery Doppler by a fetal medicine specialist if severe SGA is identified at the 18–20 week scan.

C

Karyotyping should be offered in severely SGA fetuses with structural anomalies and in those detected before 23 weeks of gestation, especially if uterine artery Doppler is normal.

C

Serological screening for congenital cytomegalovirus (CMV) and toxoplasmosis infection should be offered in severe SGA.

C

Testing for syphilis and malaria should be considered in high risk populations.

✓

Uterine artery Doppler has limited accuracy to predict adverse outcome in SGA fetuses diagnosed during the third trimester.

C

In severe SGA, the incidence of chromosomal abnormalities has been reported to be as high as 19%.<sup>104</sup> Triploidy was the most common chromosomal defect in fetuses referred before 26 weeks of gestation and trisomy 18 in those referred thereafter. Within this population, the risk of aneuploidy was found to be higher in fetuses with a structural abnormality, a normal amniotic fluid volume, a higher head circumference/AC ratio or a normal uterine artery Doppler.<sup>106,107</sup> One small study suggested that, in severely SGA fetuses, the rate of aneuploidy was 20% in fetuses presenting before 23 weeks of gestation, irrespective of the presence of structural anomalies, compared with 0% in fetuses presenting between 23–29 weeks of gestation.<sup>107</sup>

Evidence level 2+

Fetal infections are responsible for up to 5% of SGA fetuses.<sup>108</sup> The most common pathogens are reported to be cytomegalovirus (CMV), toxoplasmosis, malaria and syphilis,<sup>108</sup> although a recent multicentre study found no association between congenital toxoplasmosis and incidence of a SGA infant.<sup>109</sup> Malaria is a significant cause of preterm birth and LBW worldwide and it should be considered in those from, or who have travelled in, endemic areas.<sup>110</sup>

The predictive value of uterine artery Doppler in SGA fetuses diagnosed during the third trimester is unclear and no systematic reviews on this topic were identified in the literature search for this guideline. Severi et al.<sup>111</sup> found that uterine artery RI > 0.50 and bilateral notching were independently associated with emergency caesarean section in this population (OR 5.0, 95% CI 2.0–12.4; OR 12.2, 95% CI 2.0–74.3 respectively). Other studies have suggested that uterine artery Doppler has no predictive value.<sup>112,113</sup>

Evidence level 2+

## 8. What interventions should be considered in the prevention of SGA fetuses/neonates?

Antiplatelet agents may be effective in preventing SGA birth in women at high risk of pre-eclampsia although the effect size is small.

C

In women at high risk of pre-eclampsia, antiplatelet agents should be commenced at, or before, 16 weeks of pregnancy.

A

There is no consistent evidence that dietary modification, progesterone or calcium prevent birth of a SGA infant. These interventions should not be used for this indication.

A

**Interventions to promote smoking cessation may prevent delivery of a SGA infant. The health benefits of smoking cessation indicate that these interventions should be offered to all women who are pregnant and smoke.**

A

**Antithrombotic therapy appears to be a promising therapy for preventing delivery of a SGA infant in high-risk women. However, there is insufficient evidence, especially concerning serious adverse effects, to recommend its use.**

D

Antiplatelet agents have been extensively investigated in women at varying levels of risk for pre-eclampsia, with SGA as an outcome in both an individual patient data (IPD) meta-analysis and a Cochrane review.<sup>114,115</sup> In all pregnant women, the RR of a SGA neonate with therapy was 0.90 (95% CI 0.83–0.98) and for high risk women was 0.89 (95% CI 0.74–1.08). In the IPD meta-analysis for all pregnant women the RR was 0.90 (95% CI 0.81–1.01). The majority of the included papers randomised women at risk of pre-eclampsia and therefore it is not possible to determine the RR for aspirin in women at risk of a SGA neonate alone. The Cochrane review concluded that further information was required to assess which women are most likely to benefit, when treatment is best started and at what dose.<sup>115</sup>

Evidence level 1++

A recent systematic review and meta-analysis of five trials, with 414 women, has suggested that, with respect to women at risk of pre-eclampsia, the timing of commencement of aspirin is important.<sup>116</sup> Where aspirin was started at 16 weeks of gestation or less the RR of a SGA infant was 0.47 (95% CI 0.30–0.74) and the number needed to treat was 9 (95% CI 5.0–17.0). No reduction in risk of a SGA infant was found when aspirin was started after 16 weeks of gestation (RR 0.92, 95% CI 0.78–1.10).

A systematic review of nine trials of aspirin, in 1317 women with abnormal uterine artery Doppler, concluded that aspirin started before 16 weeks of pregnancy reduced the incidence of pre-eclampsia as well as SGA birth (RR 0.51, 95% CI 0.28–0.92); number needed to treat = 10 (95% CI 5–50).<sup>117</sup> Aspirin started after 20 weeks was not effective in reducing the risk of a SGA infant. It is not possible to determine to what extent the effect of aspirin is due to the reduction of pre-eclampsia in these women.

Dietary advice/modification interventions in pregnancy have yielded conflicting results in terms of the incidence of SGA neonates. Based on thirteen trials in 4665 women, balanced energy/protein supplementation has been associated with a modest increase in mean birth weight and a reduction in the incidence of SGA neonates (RR 0.68, 95% CI 0.56–0.84).<sup>118</sup> These effects did not appear greater in under-nourished women. In contrast, a review of two trials with 1076 women, showed high-protein supplementation reduced mean birthweight.<sup>118</sup> The impact on fetal growth of multiple-micronutrient supplementation has been addressed in nine trials involving 15 378 low risk women. Compared with supplementation of two or less micronutrients or no supplementation or a placebo, multiple micro-nutrient supplementation resulted in a decrease in SGA neonates (RR 0.92, 95% CI 0.86–0.99). However, this difference lost statistical significance when multiple micro-nutrient supplementation was compared with iron/folic acid supplementation alone.<sup>119</sup> Although maternal nutrient supplementation has been attempted in suspected SGA/FGR (including intra-amniotic administration of nutrients), there is not enough evidence to evaluate the effects.<sup>120</sup> A systematic review of six trials, involving 2783 women, found that marine oil and other prostaglandin precursor supplementation in low risk women did not alter the incidence of SGA neonates.<sup>121</sup>

Evidence level 1+

Progesterone and calcium have also been used to prevent pre-eclampsia and its complications in both high and low risk populations. In this context there is no evidence that either progesterone (four trials, 1445 women)<sup>122</sup> or calcium (four trials, 13 615 women)<sup>123</sup> is effective in reducing the incidence of SGA neonates.

Evidence level 1+

Smoking increases the risk of SGA, and 21 trials involving over 20 000 women have addressed the impact of interventions to promote smoking cessation in pregnancy.<sup>124</sup> Overall interventions reduced low birth weight (RR 0.83, 95% CI 0.73–0.95) and preterm birth but SGA was not reported in the systematic review as an outcome. Trials using cognitive behavioural therapy and incentives as the main intervention strategy demonstrated consistent improvements in birthweight.<sup>124</sup> Women who are able to stop smoking by 15 weeks of gestation can reduce the risk back to that of non-smokers.<sup>39</sup>

Evidence level 1+

Antithrombotic therapy has been used to improve outcome in women considered at risk of placental dysfunction (primarily based on previous history of pre-eclampsia, FGR or stillbirth). A systematic review of five studies involving 484 women, four of which compared heparin (either alone or with dipyridamole) with no treatment, found that heparin reduced the incidence of SGA neonates from 25% to 9% (RR 0.35, 95% CI 0.20–0.64) and also reduced the incidence of pre-eclampsia.<sup>125</sup> However, no differences were evident in perinatal mortality or preterm birth below 34 weeks. The authors concluded that while this therapy appears promising, important information about serious adverse effects and long-term childhood outcomes is unavailable.

Evidence level 2+

Antihypertensive drug therapy for mild to moderate hypertension in pregnancy does not seem to increase the risk of delivering a SGA neonate (19 trials, 2437 women, RR 1.02, 95% CI 0.89–1.16),<sup>126</sup> but treatment with oral beta-blockers was associated with an increased risk of a SGA neonate (RR 1.36, 95% CI 1.02–1.82), partly dependent on one small outlying trial involving atenolol.<sup>127</sup> Use of atenolol is therefore best avoided but no recommendation can be made regarding the best agent or target blood pressure to optimise fetal growth, especially when the fetus is known to be SGA.<sup>128</sup>

Evidence level 1+

## 9. What interventions should be considered in the preterm SGA fetus?

**Women with a SGA fetus between 24<sup>+0</sup> and 35<sup>+6</sup> weeks of gestation, where delivery is being considered, should receive a single course of antenatal corticosteroids.**

C

Women with a SGA fetus between 24<sup>+0</sup> and 35<sup>+6</sup> weeks of gestation, where delivery is being considered, should receive a single course of antenatal corticosteroids to accelerate fetal lung maturation and reduce neonatal death and morbidity.<sup>129</sup>

Evidence level 2-

Bed rest in hospital for a suspected SGA infant has only been evaluated in one trial of 107 women that showed no differences in any fetal growth parameters.<sup>130</sup>

Maternal oxygen administration has been investigated in three trials of SGA fetuses involving 94 women.<sup>131</sup> Methodological problems were identified in two of the studies, both of which had greater gestational ages of fetuses in the oxygen group. This may account for the increase in birth weight in the intervention group. Oxygenation was associated with a lower perinatal mortality (RR 0.50, 95% CI 0.32–0.81). The authors of the systematic review concluded there was not enough evidence to evaluate the benefits and risks of maternal oxygen therapy.<sup>131</sup>

Evidence level 2-

A proportion of growth restricted fetuses will be delivered prematurely and consequently be at an increased risk of developing cerebral palsy. Maternally administered magnesium sulphate has a neuroprotective effect and reduces the incidence of cerebral palsy amongst preterm infants. Australian guidelines recommend the administration of magnesium sulphate when delivery is before 30 weeks of gestation.<sup>132,133</sup>

## 10. What is the optimal method and frequency of fetal surveillance in a SGA infant and what is/are the optimal test/s to time delivery?

A variety of tests are available for surveillance of the SGA fetus. They vary in terms of the time and personnel required to perform and interpret them. The purpose of surveillance is to predict fetal acidaemia thereby



allowing timely delivery prior to irreversible end-organ damage and intrauterine fetal death.

### 10.1 Umbilical artery Doppler

**In a high-risk population, the use of umbilical artery Doppler has been shown to reduce perinatal morbidity and mortality. Umbilical artery Doppler should be the primary surveillance tool in the SGA fetus.**

**A**

**When umbilical artery Doppler flow indices are normal it is reasonable to repeat surveillance every 14 days.**

**B**

**More frequent Doppler surveillance may be appropriate in a severely SGA fetus.**



**When umbilical artery Doppler flow indices are abnormal (pulsatility or resistance index > +2 SDs above mean for gestational age) and delivery is not indicated repeat surveillance twice weekly in fetuses with end-diastolic velocities present and daily in fetuses with absent/reversed end-diastolic frequencies.**



There is compelling evidence that umbilical artery Doppler is a useful tool in the management of the high-risk pregnancy. A systematic review of 104 observational studies of accuracy, involving 19 191 fetuses, found that umbilical artery Doppler predicted compromise of fetal/neonatal wellbeing with a pooled LR+ of 3.41 (95% CI 2.68–4.34) and LR- 0.55 (95% CI 0.48–0.62).<sup>134</sup> The technique predicted fetal death (LR+ 4.37, 95% CI 0.88–21.8; LR- 0.25, 95% CI 0.07–0.91) and acidosis (LR+ 2.75, 95% CI 1.48–5.11; LR- 0.58, 0.36–0.94).<sup>134</sup>

A systematic review of RCTs of effectiveness of umbilical artery Doppler as a surveillance tool in high risk pregnancies (16 studies, testing 10 225 fetuses) found that use of umbilical artery Doppler was associated with a reduction in perinatal deaths from 1.7% to 1.2% (RR 0.71, 95% CI 0.52–0.98), number needed to treat was 203 (95% CI 103–4352).<sup>135</sup> There were also fewer inductions of labour (RR 0.89, 95% CI 0.80–0.99) and fewer caesarean sections (RR 0.90, 95% CI 0.84–0.97). No difference was found in operative vaginal births (RR 0.95, 95% CI 0.80–1.14) nor in Apgar scores < 7 at 5 minutes (RR 0.92, 95% CI 0.69–1.24).<sup>135</sup> Although not confined to SGA, this group of fetuses made up a substantial proportion of the tested population. At present the recommendation from the authors of this Cochrane review is that high risk pregnancies thought to be at risk of placental insufficiency should be monitored with Doppler studies of the umbilical artery.

Evidence level 1++

Several individual studies have also directly compared umbilical artery Doppler with other tests in the management of the SGA fetus. Umbilical artery Doppler, but not biophysical profile or cardiotography (CTG), predicted poor perinatal outcomes.<sup>136</sup> Compared to CTG, use of umbilical artery Doppler is associated with reduced use of antenatal resources (monitoring occasions, hospital admissions, inpatient stay), reduced induction of labour and emergency caesarean section for fetal distress.<sup>137–139</sup>

A variety of descriptor indices of umbilical artery Doppler waveform have been used to predict perinatal outcome. The large systematic review of test accuracy could not comment on which waveform index to use due to poor reporting in individual studies.<sup>134</sup> Although PI has been widely adopted in the UK, an analysis using receiver operator curves found that RI had the best discriminatory ability to predict a range of adverse perinatal outcomes.<sup>140</sup>

When defined by customised fetal weight standards 81% of SGA fetuses have a normal umbilical artery Doppler.<sup>141</sup> Outpatient management is safe in this group<sup>142</sup> and it may be reasonable to repeat Doppler surveillance every 14 days; one small randomised trial involving 167 SGA fetuses with normal umbilical artery Doppler investigated frequency of surveillance; twice-weekly compared to two weekly monitoring resulted in earlier deliveries and more inductions of labour with no difference in neonatal morbidity.<sup>143</sup> Compared to SGA fetuses identified before delivery and

Evidence level 2+

monitored with umbilical artery Doppler, unidentified SGA fetuses have a fourfold greater risk of adverse fetal outcome (OR 4.1, 95% CI 2.5–6.8) and fetal/infant death (OR 4.2, 95% CI 2.1–8.5).<sup>144</sup> In this large series, SGA fetuses (defined as a birth weight deviation 22–27% below the norm, equivalent to -2 SDs) were monitored with two weekly umbilical artery Doppler. However, compared to appropriate for gestational age (AGA) fetuses, SGA fetuses with a normal umbilical artery Doppler are still at increased risk of neonatal morbidity (OR 2.26, 95% CI 1.04–4.39)<sup>141</sup> and adverse neurodevelopmental outcome.<sup>145</sup>

Evidence level 2+

In SGA fetuses with abnormal umbilical artery Doppler where there is not an indication for delivery the optimal frequency of surveillance is unclear. Until definitive evidence becomes available it is reasonable to repeat surveillance twice weekly in fetuses with end-diastolic velocities present and daily in fetuses with absent or reversed end-diastolic velocities (AREDV).

Evidence level 4

In a low risk or unselected population, a systematic review of five trials, involving 14 185 women, found no conclusive evidence that routine umbilical artery Doppler benefits mother or baby.<sup>146</sup> As such, umbilical artery Doppler is not recommended for screening an unselected population.

Evidence level 1+

### 10.2 Cardiotocography (CTG)

**CTG should not be used as the only form of surveillance in SGA fetuses.**

A

**Interpretation of the CTG should be based on short term fetal heart rate variation from computerised analysis.**

A

Antenatal CTG has been compared with no intervention in a Cochrane systematic review of RCTs. Based on four trials (1627 fetuses) of high risk pregnancies there was no clear evidence that antenatal CTG improved perinatal mortality (RR 2.05, 95% CI 0.95–4.42). The included trials all employed visual analysis and only one trial was regarded as high quality.<sup>147</sup>

Evidence level 1+

Unlike conventional CTG, which has high intra- and interobserver variability, computerised CTG (cCTG) is objective and consistent.<sup>148</sup> Normal ranges for cCTG parameters throughout gestation are available.<sup>149</sup> Fetal heart rate (FHR) variation is the most useful predictor of fetal wellbeing in SGA fetuses;<sup>150,151</sup> a short term variation  $\leq 3$  ms (within 24 hours of delivery) has been associated with a higher rate of metabolic acidaemia (54.2% versus 10.5%) and early neonatal death (8.3% versus 0.5%).<sup>151</sup>

Evidence level 2+

Comparison of cCTG with traditional CTG in the Cochrane review (two trials, 469 high risk fetuses) showed a reduction in perinatal mortality with cCTG (4.2% versus 0.9%, RR 0.20, 95% CI 0.04–0.88) but no significant difference in perinatal mortality excluding congenital anomalies (RR 0.23, 95% CI 0.04–1.29), though the meta-analysis was underpowered to assess this outcome, or any other measure of adverse perinatal outcome.<sup>147</sup>

Evidence level 1-

### 10.3 Amniotic fluid volume

**Ultrasound assessment of amniotic fluid volume should not be used as the only form of surveillance in SGA fetuses.**

✓

**Interpretation of amniotic fluid volume should be based on single deepest vertical pocket.**

A

Amniotic fluid volume is usually estimated by the single deepest vertical pocket (SDVP) or amniotic fluid index (AFI) methods; although both correlate poorly with actual amniotic fluid volume.<sup>152</sup> A Cochrane systematic review (five trials, 3226 women) compared the two methods and concluded

Evidence level 1+

that there was no evidence that one method was superior in the prevention of adverse perinatal outcomes. However, compared to a SDVP < 2 cm, when an AFI  $\leq$  5 cm was used more cases of oligohydramnios were diagnosed (RR 2.39, 95% CI 1.73–3.28) and more women had induction of labour (RR 1.92, 95% CI 1.50–2.46) without an improvement in perinatal outcome.<sup>153</sup>

Evidence level 1+

The incidence of an AFI  $\leq$  5 cm in a low risk population is 1.5%.<sup>154</sup> Compared to cases with a normal AFI, the risk of perinatal mortality and morbidity was not increased in cases with isolated oligohydramnios (RR 0.7, 95% CI 0.2–2.7) nor in those with associated conditions, including SGA fetuses (RR 1.6, 95% CI 0.9–2.6). Notably over the 8 weeks after the initial diagnosis of oligohydramnios, mean EFW centile did not change significantly (remaining on 3<sup>rd</sup> centile in SGA fetuses).<sup>154</sup>

Oligohydramnios is associated with labour outcome; a systematic review of 18 studies involving 10551 women, found an AFI  $\leq$  5 cm was associated with an increased risk of caesarean section for fetal distress (RR 2.2, 95% CI 1.5–3.4) and an Apgar score < 7 at 5 minutes (RR 5.2, 95% CI 2.4–11.3) but not acidaemia.<sup>155</sup> Although older studies in high risk pregnancies have shown that a reduced SDVP is associated with increased perinatal mortality,<sup>156</sup> limited information is available about the accuracy of oligohydramnios to independently predict perinatal mortality and substantive perinatal morbidity in non-anomalous SGA fetuses monitored with umbilical artery Doppler.

Evidence level 1+

#### 10.4 Biophysical profile (BPP)

**Biophysical profile should not be used for fetal surveillance in preterm SGA fetuses.**

A

The biophysical profile (BPP) includes four acute fetal variables (breathing movement, gross body movement, tone and CTG, and amniotic fluid volume each assigned a score of 2 (if normal) or 0 (if abnormal). Reducing BPP score is associated with lower antepartum umbilical venous pH and increasing perinatal mortality.<sup>157</sup> The BPP is time consuming and the incidence of an equivocal result (6/10) is high (15–20%) in severely SGA fetuses,<sup>158</sup> although this rate can be reduced if cCTG is used instead of conventional CTG.<sup>150</sup>

A systematic review of the effectiveness of BPP as a surveillance tool in high risk pregnancies (five studies, testing 2974 fetuses) found that the use of BPP was not associated with a reduction in perinatal deaths (RR 1.33, 95% CI 0.60–2.98) or Apgar scores < 7 at 5 minutes (RR 1.27, 95% CI 0.85–1.92).<sup>159</sup> Combined data from the two high quality trials suggested an increased risk of caesarean section in the BPP group (RR 1.60, 95% CI 1.05–2.44) with no improvement in perinatal outcome.<sup>159</sup>

Evidence level 1+

Early observational studies in high risk non-anomalous fetuses reported very low false negative rates for antepartum acidaemia (0%) and perinatal death within 7 days of a normal test (0.2%).<sup>157,160</sup> However more recent studies in preterm severely SGA fetuses suggest the BPP is not an accurate predictor of fetal acidaemia<sup>150,161</sup> and that the test has much higher false negative rates (11%) in this group.<sup>161</sup> BPP is not recommended for fetal surveillance in the preterm SGA fetus.

Evidence level 2+

#### 10.5 Middle cerebral artery (MCA) Doppler

**In the preterm SGA fetus, middle cerebral artery (MCA) Doppler has limited accuracy to predict acidaemia and adverse outcome and should not be used to time delivery.**

B

**In the term SGA fetus with normal umbilical artery Doppler, an abnormal middle cerebral artery Doppler (PI < 5<sup>th</sup> centile) has moderate predictive value for acidosis at birth and should be used to time delivery.**

C

Cerebral vasodilatation is a manifestation of the increase in diastolic flow, a sign of the 'brain-sparing effect' of chronic hypoxia, and results in decreases in Doppler indices of the middle cerebral artery (MCA) such as the PI. Reduced MCA PI or MCA PI/umbilical artery PI (cerebroplacental ratio) is therefore an early sign of fetal hypoxia in SGA fetuses.<sup>162–165</sup>

No systematic reviews of effectiveness of MCA Doppler as a surveillance tool in high risk or SGA fetuses were identified. A systematic review of 31 observational studies (involving 3337 fetuses) found that MCA Doppler had limited predictive accuracy for adverse perinatal outcome (LR+ 2.79, 95% CI 1.10–1.67; LR- 0.56, 95% CI 0.43–0.72) and perinatal mortality (LR+ 1.36, 95% CI 1.10–1.67; LR- 0.51, 95% CI 0.29–0.89).<sup>165</sup> Most studies investigating MCA Doppler as a predictor of adverse outcome in preterm SGA fetuses have reported low predictive value,<sup>165–167</sup> especially when umbilical artery Doppler is abnormal. In the largest study of predictors of neonatal outcome in SGA neonates of less than 33 weeks gestational age (n = 604), although MCA PI < -2 SDs was associated with neonatal death (LR 1.12, 95% CI 1.04–1.21) and major morbidity (LR 1.12, 95% CI 1.1–1.33), it was not a statistically significant predictor of outcome on logistic regression.<sup>168</sup> Initial findings of a pre-terminal increase (reversal) of MCA PI have not been confirmed in subsequent reports.<sup>169,170</sup>

Evidence level 1+

MCA Doppler may be a more useful test in SGA fetuses detected after 32 weeks of gestation where umbilical artery Doppler is typically normal.<sup>171</sup> Studies suggest an elevated MCA PI is associated with emergency caesarean section and neonatal admission.<sup>172,173</sup> In one study of 210 term SGA fetuses with normal umbilical artery Doppler, MCA PI < 5<sup>th</sup> centile was predictive of caesarean section for nonreassuring fetal status (OR 18.0, 95% CI 2.84–750) and neonatal metabolic acidosis, defined as umbilical artery pH < 7.15 and base deficit > 12 mEq/L (OR 9.0, 95% CI 1.25–395).<sup>174</sup> Based on this evidence it is reasonable to use MCA Doppler to time delivery in the term SGA fetus with normal umbilical artery Doppler.

Evidence level 2-

### 10.6 Ductus venosus (DV) and umbilical vein (UV) Doppler

**Ductus venosus Doppler has moderate predictive value for acidaemia and adverse outcome.**

A

**Ductus venosus Doppler should be used for surveillance in the preterm SGA fetus with abnormal umbilical artery Doppler and used to time delivery.**

✓

The Ductus venosus (DV) Doppler flow velocity pattern reflects atrial pressure-volume changes during the cardiac cycle. As FGR worsens velocity reduces in the DV a-wave owing to increased afterload and preload, as well as increased end-diastolic pressure, resulting from the direct effects of hypoxia/acidaemia and increased adrenergic drive.<sup>175</sup> A retrograde a-wave and pulsatile flow in the umbilical vein (UV) signifies the onset of overt fetal cardiac compromise.<sup>175</sup>

No systematic reviews of effectiveness of venous Doppler as a surveillance tool in high risk or SGA fetuses were identified. A systematic review of 18 observational studies (involving 2267 fetuses) found that DV Doppler had moderate predictive accuracy for the prediction of perinatal mortality in high risk fetuses with placental insufficiency with a pooled LR+ of 4.21 (95% CI 1.98–8.96) and LR- of 0.43 (95% CI 0.30–0.61).<sup>175</sup> For prediction of adverse perinatal outcome the results were LR+ 3.15 (95% CI 2.19–4.54) and LR- 0.49 (95% CI 0.40–0.59).<sup>176</sup>

Evidence level 1+

Observational studies have identified venous Doppler as the best predictor of acidaemia.<sup>150,177</sup> Turan et al.<sup>150</sup> reported an OR of 5.68 (95% CI 1.67–19.32) for an increased DV PI for veins (PIV) and 45.0 (95% CI 5.0–406.5) for UV pulsation compared to 2.12 (95% CI 0.66–6.83) for AREDV in the umbilical artery. In the large study of predictors of neonatal outcome in preterm SGA neonates referred to above, gestational age was the most significant determinant of intact survival until 29 weeks of gestation but DV Doppler alone predicted intact survival beyond this gestational age.<sup>168</sup>

Evidence level 2-

## 11. What is the optimal gestation to deliver the SGA fetus?

**In the preterm SGA fetus with umbilical artery AREDV detected prior to 32 weeks of gestation, delivery is recommended when DV Doppler becomes abnormal or UV pulsations appear, provided the fetus is**

✓

considered viable and after completion of steroids. Even when venous Doppler is normal, delivery is recommended by 32 weeks of gestation and should be considered between 30–32 weeks of gestation.

If MCA Doppler is abnormal, delivery should be recommended no later than 37 weeks of gestation.



In the SGA fetus detected after 32 weeks of gestation with an abnormal umbilical artery Doppler, delivery no later than 37 weeks of gestation is recommended.



In the SGA fetus detected after 32 weeks of gestation with normal umbilical artery Doppler, a senior obstetrician should be involved in determining the timing and mode of birth of these pregnancies. Delivery should be offered at 37 weeks of gestation.



At present there is no effective intervention to alter the course of FGR except delivery. Timing delivery is therefore a critical issue in order to balance the risks of prematurity against those of continued intrauterine stay; death and organ damage due to inadequate tissue perfusion.<sup>178</sup>

Gestational age is a critical determinant in decision-making. Various tools exist to predict survival in very preterm births, such as the prematurity risk evaluation measure (PREM) score, which is a system derived from UK cohorts and incorporates gestational age and EFW.<sup>179</sup> In FGR detected prior to 33 weeks of gestation, gestational age was found to be the most significant determinant of total survival until 27 weeks and intact survival until 29 weeks.<sup>168</sup>

The second critical determinant in decision-making is the interpretation of surveillance tests which should accurately predict perinatal outcomes of importance (death, major morbidity and neurodevelopmental delay). Existing studies investigating the relationship between fetal surveillance tests and neurodevelopmental outcome have recently been reviewed.<sup>185</sup> Several studies have reported the sequence of changes in Doppler and biophysical parameters as FGR worsens.<sup>170,181,182</sup> While most fetuses showed a deterioration of arterial Doppler indices before the occurrence of an abnormal DV PIV or biophysical abnormalities, the relationship between venous Doppler and biophysical abnormalities was not consistent. For example, more than 50% of fetuses delivered because of cCTG abnormalities had a normal DV PIV.<sup>181</sup>

### 11.1 Preterm SGA fetus

The RCT growth restriction intervention trial (GRIT) compared the effect of delivering early (after completion of a steroid course) with delaying birth for as long as possible (i.e. until the obstetrician was no longer uncertain).<sup>183</sup> Between 24–36 weeks of gestation, 588 fetuses were recruited. Median time-to-delivery was 0.9 days in the early group and 4.9 days in the delay group. There was no difference in total deaths prior to discharge (10% versus 9%, OR 1.1, 95% CI 0.6–1.8), inferring obstetricians are delivering sick preterm fetuses at about the correct time to minimise mortality.<sup>183</sup> At 2 years overall rates of death (12% versus 11% respectively) or severe disability, defined as a Griffiths developmental quotient  $\leq 70$  or presence of motor or perceptual severe disability (7% versus 4%) were similar (OR 1.1, 95% CI 0.7–1.8).<sup>184</sup> These findings are consistent with observational studies suggesting that fetal deterioration does not have an independent impact on neurodevelopment in early-onset FGR.<sup>180</sup>

Evidence level 1+

On the basis of GRIT, the evidence reviewed in Section 10 and that perinatal mortality increases from 12% in fetuses with umbilical artery AREDV to 39% when DV PIV is increased (and 41% with absence or reversal of DV A-wave)<sup>178</sup> it would seem reasonable to recommend delivery when the DV Doppler becomes abnormal or UV pulsations are present, provided the fetus is considered viable (usually when gestational age is  $\geq 24$  weeks and EFW is  $> 500$  g)<sup>181, 185</sup> and after completion of steroids. Based on available evidence it is not known whether delivery should be recommended as soon as the DV PIV becomes abnormal or whether delivery should be deferred until the DV

Evidence level 4

A-wave becomes absent/reversed. This key question is being addressed in the ongoing trial of umbilical and fetal flow in a European RCT which aims to determine whether delivery based on reduced short term variability on cCTG leads to better neurodevelopmental outcome in surviving infants than delivery based on DV Doppler.<sup>186</sup>

Evidence level 4

By 31 weeks of gestation, neonatal mortality and disability rates in this population are low; in GRIT, mortality and disability rates in fetuses delivered at 31–36 weeks were 5% and 4% respectively<sup>183</sup> while in the large series of early onset FGR reported by Baschat et al.,<sup>168</sup> mortality was 8.6% in fetuses delivered at 31 weeks and 2.6% in those delivered at 32 weeks. Given the mortality associated with umbilical artery AREDV alone<sup>178</sup> delivery should be considered based on this finding alone after 30 weeks of gestation and recommended no later than 32 weeks of gestation.

### 11.2 Near term / term SGA fetus

One randomised equivalence trial exists comparing the effect of induction of labour or expectant monitoring in women beyond 36 weeks of gestation with suspected FGR (defined as a fetal AC or EFW < 10<sup>th</sup> centile or flattening of the growth curve in the third trimester, as judged by the clinician).<sup>187</sup> Between 36–41 weeks of gestation, 650 fetuses were recruited; 14 had umbilical artery AREDV. Expectant monitoring consisted of twice weekly CTG and ultrasound examinations. Induction group infants were delivered 9.9 (95% CI 8.6–11.3) days earlier and weighed 130 g (95% CI 71–188) less. A total of 5.3% infants in the induction group experienced adverse outcome (defined as death, umbilical artery pH < 7.05 or admission to intensive care) compared to 6.1% in the expectant monitoring group (difference -0.8%, 95% CI -4.3–3.2). Caesarean section was performed in 14% of women in both groups.<sup>187</sup> Based on these results, it is reasonable to offer delivery in SGA infants at 37 weeks of gestation.

Evidence level 1+

Given the evidence reviewed in Section 10 and the increased risk of adverse outcomes in term/near term SGA fetuses with increased umbilical artery PI and those with a normal umbilical artery Doppler but reduced MCA PI, delivery should be recommended by 37 weeks of gestation.

Evidence level 2-

An algorithm to assist in the management of the SGA fetus is provided in Appendix 3.

## 12. How should the SGA fetus be delivered?

**In the SGA fetus with umbilical artery AREDV delivery by caesarean section is recommended.**



**In the SGA fetus with normal umbilical artery Doppler or with abnormal umbilical artery PI but end-diastolic velocities present, induction of labour can be offered but rates of emergency caesarean section are increased and continuous fetal heart rate monitoring is recommended from the onset of uterine contractions.**



**Early admission is recommended in women in spontaneous labour with a SGA fetus in order to instigate continuous fetal heart rate monitoring.**



Compared to appropriate-for-gestational age fetuses, term and near term SGA fetuses are at increased risk of FHR decelerations in labour, emergency caesarean section for suspected fetal compromise and metabolic acidemia at delivery. This reflects a lower prelabour pO<sub>2</sub> and pH,<sup>188</sup> greater cord compression secondary to oligohydramnios<sup>189</sup> and a greater fall in pH and higher lactate levels when FHR decelerations are present.<sup>190</sup> Reported rates of emergency CS for suspected fetal compromise vary from 6–45% but a rate of ~15% is probably reasonable for fetuses with an AC or EFW < 10<sup>th</sup> centile, with higher rates in those with serial AC or EFW measurements suggestive of FGR.<sup>98,191,192</sup> No RCTs of mode of delivery in the SGA fetus were identified.

Delivery in all recent studies reporting outcome of viable SGA fetuses with umbilical artery AREDV has been by caesarean section and thus it is not possible to determine the likelihood of adverse outcome (including emergency CS for suspected fetal compromise) associated with induced/spontaneous labour. Older series report rates of intrapartum fetal heart decelerations necessitating CS of 75–95%.<sup>193,194</sup> More recent prospective data on the outcome of labour in SGA fetuses with an abnormal umbilical artery Doppler but end-diastolic velocities is also extremely limited; suspected fetal compromise (necessitating emergency CS) has been reported in 17–32% of such cases, compared to 6–9% in SGA fetuses with normal umbilical artery Doppler.<sup>191,192,195</sup> Although, it is acknowledged that knowledge of Doppler may lower obstetricians' threshold for emergency CS.<sup>196</sup> The offer of induction of labour with continuous FHR monitoring is therefore reasonable in term and near term fetuses, as well as SGA fetuses without umbilical artery AREDV. The procedures for induction of labour should follow existing guidance.<sup>197</sup>

### 13. Suggested audit topics

All units should audit their antenatal detection rate of the SGA neonate. Definition of a SGA neonate should be based on customised birthweight standards. Suggested auditable standards are as follows:

- All women should have a formal assessment of their risk of delivering a SGA neonate at booking.
- All women with a major risk factor for a SGA neonate should be offered serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler.
- All women with a SGA fetus should have serial ultrasound measurement of fetal size and assessment of wellbeing with umbilical artery Doppler.
- All women with a SGA fetus where delivery is considered between 24<sup>+0</sup> and 35<sup>+6</sup> weeks of gestation should receive a single course of antenatal corticosteroids.

### 14. What are the areas for future research?

Research may be required to evaluate the effectiveness of/determine:

- How combinations of risk factors for a SGA neonate (historical, biochemical and ultrasound) relate to each other in the individual woman.
- Interventions, specifically aspirin, in women classified as being at high risk of delivering a SGA neonate based on combined historical, biochemical, and ultrasound marker screening in the first trimester.
- Introducing customised SFH and EFW charts into clinical practice on substantive clinical endpoints (perinatal mortality/morbidity and service utilisation).
- Routine third trimester ultrasound assessment of fetal size combined with umbilical artery Doppler on substantive clinical endpoints (perinatal mortality/morbidity and service utilisation).
- Oxygen therapy in severe early-onset SGA foetuses associated with umbilical artery AREDV on substantive clinical endpoints (perinatal mortality/morbidity and service utilisation).
- Optimal frequency and content of fetal surveillance in SGA fetuses with both a normal umbilical artery Doppler and also an abnormal umbilical artery Doppler but with end-diastolic frequencies present.
- Measuring amniotic fluid volume and MCA Doppler in the near term SGA fetuses with a normal umbilical artery Doppler on substantive clinical endpoints (perinatal morbidity and service utilisation).
- Potential health economic benefit of investment in maternity services to provide recommendations in this guideline and future health outcomes of the children.

## References

1. Clausson B, Gardosi J, Francis A, Cnattingius S. Perinatal outcome in SGA births defined by customised versus population-based birthweight standards. *BJOG* 2001;108:830–4.
2. Figueras F, Figueras J, Meler E, Eixarch E, Coll O, Gratecos E, et al. Customised birthweight standards accurately predict perinatal morbidity. *Arch Dis Child Fetal Neonat Ed* 2007;92:277–80.
3. Chang TC, Robson SC, Boys RJ, Spencer JA. Prediction of the small for gestational age infant: which ultrasonic measurement is best? *Obstet Gynecol* 1992;80:1030–8.
4. Alberry M, Soothill P. Management of fetal growth restriction. *Arch Dis Child Fetal Neonat Ed* 2007;92:62–7.
5. Odibo AO, Francis A, Cahill AG, Macones GA, Crane JP, Gardosi J. Association between pregnancy complications and small-for-gestational-age birth weight defined by customized fetal growth standards versus a population-based standard. *J Matern Fetal Neonatal Med* 2011;24:411–7.
6. Wolfe HM, Gross TL, Sokol RJ. Recurrent small for gestational age birth: perinatal risks and outcomes. *Am J Obstet Gynecol* 1987;157:288–93.
7. Kleijer ME, Dekker GA, Heard AR. Risk factors for intrauterine growth restriction in a socio-economically disadvantaged region. *J Matern Fetal Neonatal Med* 2005;18:23–30.

8. Ananth CV, Peltier MR, Chavez MR, Kirby RS, Getahun D, Vintzileos AM. Recurrence of ischemic placental disease. *Obstet Gynecol* 2007;110:128–33.9.
9. Gestation Network Growth Charts. [[https://www.gestation.net/fetal\\_growth/download\\_grow.htm](https://www.gestation.net/fetal_growth/download_grow.htm)].
10. Gardosi J, Kady SM, McGeown P, Francis A, Tonks A. Classification of stillbirth by relevant condition of death (ReCoDe): population based cohort study. *BMJ* 2005;331:113–7.
11. Shah PS, Zao J. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses. *BJOG* 2009;116:1425–42.
12. Spinillo A, Capuzzo E, Piazzì G, Nicola S, Colonna L, Iasci A. Maternal high-risk factors and severity of growth deficit in small for gestational age infants. *Early Hum Dev* 1994;38:35–43.
13. Lang JM, Lieberman E, Cohen A. A comparison of risk-factors for preterm labour and term small-for-gestational-age birth. *Epidemiology* 1996;7:369–76.
14. Howarth C, Gazis A, James D. Associations of type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. *Diabet Med* 2007;24:1229–34.
15. Fink JC, Schwartz M, Benedetti TJ, Stehman-Breen CO. Increased risk of adverse maternal and fetal outcomes among women with renal disease. *Paediatr Perinat Epidemiol* 1998;12:277–87.
16. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. *Obstet Gynecol* 1995;86:555–9.
17. Allen VM, Joseph KS, Murphy KE, Magee LA, Ohlsson A. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: a population based study. *BMC Pregnancy Childbirth* 2004;4:17–25.
18. Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy outcomes in women with systemic lupus erythematosus. *J Matern Fetal Med* 2001;10:91–6.
19. Drenthen W, Pieper PG, Roos-Hesselink JW, van Lottum WA, Voors AA, Mulder BJ, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. *J Am Coll Cardiol* 2007;49:2303–11.
20. McCowan L, Horgan RP. Risk factors for small for gestational age infants. *Best Pract Res Clin Obstet Gynaecol* 2009;23:779–93.
21. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. *Arch Gen Psychiatry* 2010;67:1012–24.
22. Odibo AO, Nelson D, Stamilio DM, Sehdev HM, Macones GA. Advanced maternal age is an independent risk factor for intrauterine growth restriction. *Am J Perinatol* 2006;23:325–8.
23. Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. *Bull World Health Organ* 1987;65:663–737.
24. Alexander GR, Wingate MS, Mor J, Boulet S. Birth outcomes of Asian-Indian-americans. *Int J Gynaecol Obstet* 2007;97:215–20.
25. Shah PS, Knowledge Synthesis Group on Determinants of LBW/PT Births. Parity and low birth weight and pre-term birth: a systematic review and meta-analyses. *Acta Obstet Gynecol Scand* 2010;89:862–75.
26. Blumenshine P, Egarter S, Barclay CJ, Cubbin C, Braveman PA. Socioeconomic disparities in adverse birth outcomes: a systematic review. *Am J Prev Med* 2010;39:263–72.
27. Shah PS, Zao J, Ali S. Maternal marital status and birth outcomes: a systematic review and meta-analyses. *Matern Child Health J* 2011;15:1097–109.
28. Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based centiles. *Am J Obstet Gynecol* 2009;201:1–8.
29. Kramer MS, Platt R, Yang H, McNamara H, Usher RH. Are all growth restricted newborns created equal(ly)? *Pediatrics* 1999;103:599–602.
30. Han Z, Mulla S, Beyene J, Liao G, McDonald SD; Knowledge Synthesis Group. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. *Int J Epidemiol* 2011;40:65–101.
31. Shah PS, Shah V, Knowledge Synthesis Group on Determinants of LBW/PT Births. Influence of maternal birth status on offspring: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand* 2009;88:1307–18.
32. McCowan LM, Roberts CT, Dekker GA, Taylor RS, Chan EH, Kenny LC, et al. Risk factors for small-for-gestational-age infants by customised birthweight centiles: data from an international prospective cohort study. *BJOG* 2010;117:1599–607.
33. Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. *JAMA* 2006;295:1809–23.
34. Weiss JL, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, et al. Threatened abortion: A risk factor for poor pregnancy outcome, a population-based screening study. *Am J Obstet Gynecol* 2004;190:745–50.
35. Shah JS, Shah J, Knowledge Synthesis Group on Determinants of LBW/PT Births. Maternal exposure to domestic violence and pregnancy and birth outcomes: a systematic review and meta-analysis. *J Womens Health* 2010;19:2017–31.
36. National Institute for Health and Clinical Excellence (NICE). Antenatal care. *Routine care for the healthy pregnant woman*. London: NICE; 2008.
37. Jaddoe VW, Bakker R, Hofman A, Mackenbach JP, Moll HA, Steegers EA, et al. Moderate alcohol consumption during pregnancy and the risk of low birth weight and preterm birth. The generation R study. *Ann Epidemiol* 2007;17:834–40.
38. Gouin K, Murphy K, Shah PS, Knowledge Synthesis Group on Determinants of LBW/PT Births. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. *Am J Obstet Gynecol* 2011;204:340:1–12.
39. McCowan LM, Dekker GA, Chan E, Stewart A, Chappell LC, Hunter M, et al. Spontaneous preterm birth and small for gestational age infants in women who stop smoking early in pregnancy: prospective cohort study. *BMJ* 2009;338:b1081.
40. CARE Study group. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. *BMJ* 2008;337:a2332.
41. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. *Obstet Gynecol* 2004;103:551–63.
42. Krulwich CJ, Herman AA, Yu Kf, Johnson YR. Does changing paternity contribute to the risk of intrauterine growth retardation? *Paediatr Perinat Epidemiol* 1997;11(Suppl 1):41–7.
43. Shah PS, Knowledge Synthesis Group on determinants of LBW/PT births. Paternal factors and low birthweight, preterm and small for gestational age births: a systematic review. *Am J Obstet Gynecol* 2010;202:103–23.
44. Jaquet D, Swaminathan S, Alexander GR, Czernichow P, Collin D, Salihu HM, et al. Significant paternal contribution to the risk for small for gestational age. *BJOG* 2005;112:153–9.45.
45. The SCOPE Pregnancy Research Study. [<http://www.scopestudy.net/>].
46. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. *J Obstet Gynaecol Can* 2008;30:918–49.
47. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2008;8:33.
48. Huerta-Enochian G, Katz V, Erfurth S. The association of abnormal alpha-fetoprotein and adverse pregnancy outcome; does increased fetal surveillance affect pregnancy outcome? *Am J Obstet Gynecol* 2001;184:1549–53.
49. Wenstrom KD, Hauth JC, Goldenberg RL, DuBard MB, Lea C. The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotrophin levels. *Am J Obstet Gynecol* 1995;173:1292–6.



50. Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH. First-Trimester Biochemical Markers of Aneuploidy and the Prediction of Small-for-Gestational Age Fetuses. *Obstetrical & Gynaecological Survey* 2009; 64:370-2.
51. Fox NS, Shalom D, Chasen ST. Second-trimester fetal growth as a predictor of poor obstetric and neonatal outcome in patients with low first trimester serum pregnancy-associated plasma protein-A and a euploid fetus. *Ultrasound Obstet Gynecol* 2009;33:34-8.
52. Kirkegaard I, Henriksen TB, Ulbjerg N. Early fetal growth, PAPP-A and free  $\beta$ -hCG in relation to risk of delivering a small-for-gestational age infant. *Ultrasound Obstet Gynecol* 2011;37:341-7.
53. Lin S, Shimizu I, Suehara N, Nakayama M, Aono T. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. *Obstet Gynecol* 1995;85:760-5.
54. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. *Hum Reprod* 2004;19:206-9.
55. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariate meta-analysis. *CMAJ* 2008;178:701-11.
56. Ghi T, Contro A, Youssef F, Giorgetta F, Farina A, Pilu G, et al. Persistence of increased uterine artery resistance in the third trimester and pregnancy outcome. *Ultrasound Obstet Gynecol* 2010;36:577-81.
57. Stampalija T, Gyte GML, Alfirevic Z. Utero-placental Doppler ultrasound for improving pregnancy outcome. *Cochrane Database Syst Rev* 2010;(9):CD008363.
58. Pilalis A, Souka AP, Antsaklis P, Daskalakis G, Papantoniou N, Mesogitis S, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks gestation. *Ultrasound Obstet Gynecol* 2007;29:135-40.
59. Filippi E, Staughton J, Peregrine E, Jones P, Huttly W, Peebles DM, et al. Uterine artery Doppler and adverse pregnancy outcome in women with extreme levels of fetoplacental proteins used for Down syndrome screening. *Ultrasound Obstet Gynecol* 2011;37:520-27.
60. Dane B, Dane C, Kiray M, Cetin A, Koldas M, Erginbas M. Correlation between first-trimester maternal serum markers, second trimester uterine artery doppler indices and pregnancy outcome. *Gynecol Obstet Invest* 2010;70:126-31.
61. Costa SL, Proctor L, Dodd JM, Toal M, Okun N, Johnson JA, et al. Screening for placental insufficiency in high risk pregnancies: Is earlier better? *Placenta* 2008;29:1034-40.
62. Goetzinger KR, Cahill AG, Macones GA, Odibo AO. Echogenic bowel on second-trimester ultrasonography. *Obstet Gynecol* 2011;117:1341-8.
63. Harlev A, Levy A, Zaulan Y, Koifman A, Mazor M, Wiznitzer A, et al. Idiopathic bleeding during the second half of pregnancy as a risk factor for adverse perinatal outcome. *J Matern Fetal Neonatal Med* 2008;21:331-5.
64. Tikkanen M. Placental abruption: epidemiology, risk factors and consequences. *Acta Obstet Gynecol Scand* 2011;90:140-9.
65. Bais JM, Eskes M, Pel M, Bonsel GJ, Bleker OP. Effectiveness of detection of intrauterine growth retardation by abdominal palpation as screening test in a low risk population: an observational study. *Eur J Obstet Gynecol Reprod Biol* 2004;116:164-9.
66. Kean LH, Liu DTY. Antenatal care as a screening tool for the detection of small for gestational age babies in the low risk population. *J Obstet Gynecol* 1996;16:77-82.
67. Hall MH, Chng PK, MacGillivray I. Is routine antenatal care worthwhile? *Lancet* 1980;2:78-80.
68. Rosenberg K, Grant JM, Hepburn M. Antenatal detection of growth retardation: actual practice in a large maternity hospital. *BJOG* 1982;89:12-5.
69. Morse K, Williams A, Gardosi J. Fetal growth screening by fundal height measurement. *Best Pract Res Clin Obstet Gynaecol* 2009;23:809-18.
70. Belizán JM, Villar J, Nardin JC, Malamud J, De Vicuña LS. Diagnosis of intrauterine growth retardation by a simple clinical method: measurement of uterine height. *Am J Obstet Gynecol* 1978;131:643-6.
71. Cnattingius S, Axelsson O, Lindmark G. Symphysis-fundus measurements and intrauterine growth retardation. *Acta Obstet Gynecol Scand* 1984;63:335-40.
72. Mathai M, Jairaj P, Muthurathnam S. Screening for light-for-gestational age infants: a comparison of three simple measurements. *BJOG* 1987;94:217-21.
73. Persson B, Stangenberg M, Lunell NO, Brodin U, Holmberg NG, Vaclavinkova V. Prediction of size of infants at birth by measurement of symphysis fundus height. *BJOG* 1986;93:206-11.
74. Bailey SM, Sarmandal P, Grant JM. A comparison of three methods of assessing inter-observer variation applied to measurements of symphysis-fundus height. *BJOG* 1989;96:1266-71.
75. Pearce JM, Campbell S. A comparison of symphysis-fundal height and ultrasound as screening tests for light-for-gestational age infants. *BJOG* 1987;94:100-4.
76. Neilson JP. Symphysis-fundal height in pregnancy. *Cochrane Database Syst Rev* 2000;(2):CD000944.
77. Gardosi J, Francis A. Controlled trial of fundal height measurement plotted on customised antenatal growth charts. *BJOG* 1999;106:309-17.
78. Wright J, Morse K, Kady S, Francis A. Audit of fundal height measurement plotted on customised growth charts. *MIDIRS Midwifery Dig* 2006;16:341-5.
79. Chauhan SP, Magann EF. Screening for fetal growth restriction. *Clin Obstet Gynecol* 2006;49:284-94.
80. Chauhan SP, Cole J, Sanderson M, Magann EF, Scardo JA. Suspicion of intrauterine growth restriction: Use of abdominal circumference alone or estimated fetal weight below 10%. *J Mat Fetal Neonat Med* 2006;19:557-62.
81. Kayem G, Grange G, Breart G, Goffinet F. Comparison of fundal height measurement and sonographically measured fetal abdominal circumference in the prediction of high and low birth weight at term. *Ultrasound Obstet Gynecol* 2009;34:566-71.
82. Scioscia M, Vimercati A, Ceci O, Vicino M, Selvaggi LE. Estimation of birth weight by two-dimensional ultrasonography: a critical appraisal of its accuracy. *Obstet Gynecol* 2008;111:57-65.
83. Chien PF, Owen P, Khan KS. Validity of ultrasound estimation of fetal weight. *Obstet Gynecol* 2000;95:856-60. 84. Robson SC, Gallivan S, Walkinshaw SA, Vaughan J, Rodeck CH. Ultrasonic estimation of fetal weight; use of targeted formulas in small for gestational age fetuses. *Obstet Gynecol* 1993;82:359-64.
85. Thiebaugeorges O, Fresson J, Audibert F, Guihard-Costa AM, Frydman R, Droulle P. Diagnosis of small-for-gestational age fetuses between 24 and 32 weeks, based on standard sonographic measurements. *Ultrasound Obstet Gynecol* 2000;16:49-55.
86. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body and femur measurements—a prospective study. *Am J Obstet Gynecol* 1985;151:333-7.
87. Chitty LS, Altman DG, Henderson A, Campbell S. Charts of fetal size: 3. Abdominal measurements. *BJOG* 1994;101:125-31.
88. Pang MW, Leung TN, Sahota DS, Lau TK, Chang AM. Customizing fetal biometric charts. *Ultrasound Obstet Gynecol* 2003;22:271-6.
89. de Jong CL, Gardosi J, Baldwin C, Francis A, Dekker GA, van Geijn HP. Fetal weight gain in a serially scanned high-risk population. *Ultrasound Obstet Gynecol* 1998;11:39-43.
90. de Jong CL, Francis A, Van Geijn HP, Gardosi J. Customised fetal weight limits for antenatal detection of fetal growth restriction. *Ultrasound Obstet Gynecol* 2000;15:36-40.

91. Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gülmezoglu AM, et al. A global reference for fetal-weight and birthweight percentiles. *Lancet* 2011;377:1855–61.
92. Mongelli M, Gardosi J. Reduction of false-positive diagnosis of fetal growth restriction by application of customized fetal growth standards. *Obstet Gynecol* 1996;88:844–8.
93. Bricker L, Neilson JP, Dowswell T. Routine ultrasound in late pregnancy (after 24 weeks' gestation). *Cochrane Database Syst Rev* 2008;(4):CD001451.
94. McKenna D, Tharmaratnam S, Mahsud S, Bailie C, Harper A, Dornan J. A randomized trial using ultrasound to identify the high-risk fetus in a low-risk population. *Obstet Gynecol* 2003;101:626–32.
95. Owen P, Donnet ML, Ogston SA, Christie AD, Howie PW, Patel NB. Standards for ultrasound fetal growth velocity. *BJOG* 1996;103:60–9.
96. Larsen T, Petersen S, Greisen G, Larsen JF. Normal fetal growth evaluated by longitudinal ultrasound examinations. *Early Hum Dev* 1990;24:37–45.
97. Royston P. Calculation of unconditional and conditional reference intervals for foetal size and growth from longitudinal measurements. *Stat Med* 1995;14:1417–36.
98. Robson SC, Chang TC. Intrauterine growth retardation. In: Reed G, Claireaux A, Cockburn F, editors. *Diseases of the Fetus and the Newborn*. 2nd ed. London: Chapman and Hall; 1994. p.277–86.
99. Chang TC, Robson SC, Spencer JA, Gallivan S. Identification of fetal growth retardation: comparison of Doppler waveform indices and serial ultrasound measurements of abdominal circumference and fetal weight. *Obstet Gynecol* 1993;82:230–6.
100. Chang TC, Tobson SC, Spencer JA, Gallivan S. Prediction of perinatal morbidity at term in small fetuses: comparison of fetal growth and Doppler ultrasound. *BJOG* 1994;101:422–7.
101. Mongelli M, Sverker EK, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time interval and ultrasound error. *Obstet Gynecol* 1998;92:908–12.
102. Chauhan SP, Magann EF, Doherty DA, Ennen CS, Niederhauser A, Morrison JC. Prediction of small for gestational age newborns using ultrasound estimated and actual amniotic fluid volume: published data revisited. *ANZJOG* 2008;48:160–4.
103. Owen P, Khan KS, Howie P. Single and serial estimates of amniotic fluid volume and umbilical artery resistance in the prediction of intrauterine growth restriction. *Ultrasound Obstet Gynecol* 1999;13:415–9.
104. Niknafs P, Sibbald J. Accuracy of single ultrasound parameters in detection of fetal growth restriction. *Am J Perinatol* 2001;18:325–34.
105. Morris RK, Malin G, Robson SC, Kleijnen J, Zamora J, Khan KS. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. *Ultrasound Obstet Gynecol* 2011;37:135–42.
106. Snijders RJ, Sherrod C, Gosden CM, Nicolaidis KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. *Am J Obstet Gynecol* 1993;168:547–55.
107. Anandakumar C, Chew S, Wong YC, Malarvisy G, Po LU, Ratnam SS. Early asymmetric IUGR and aneuploidy. *J Obstet Gynaecol Res* 1996;22:365–70.
108. Hendrix N, Berghella V. Non-placental causes of intrauterine growth restriction. *Semin Perinatol* 2008;32:161–5.
109. Freeman K, Oakley L, Pollak A, Buffolano W, Petersen E, Semprini AE, et al. Association between congenital toxoplasmosis and preterm birth, low birthweight and small for gestational age birth. *BJOG* 2005;112:31–7.
110. Yakoob MY, Zakaria A, Waqar SN, Zafar S, Wahla AS, Zaidi SK, et al. Does malaria during pregnancy affect the newborn? *J Pak Med Assoc* 2005;55:543–6.
111. Severi FM, Bocchi C, Visentin A, Falco P, Cobellis L, Florio P, et al. Uterine and fetal cerebral Doppler predict the outcome of third-trimester small-for-gestational age fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol* 2002;19:225–8.
112. Vergani P, Roncaglia N, Ghidini A, Crippa I, Camerani I, Orsenigo F, et al. Can adverse neonatal outcome be predicted in late preterm or term fetal growth restriction? *Ultrasound Obstet Gynecol* 2010;36:166–70.
113. Oros D, Figueras F, Cruz-Martinez R, Meler E, Munmany M, Gratacos E. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses. *Ultrasound Obstet Gynecol* 2011;37:191–5.
114. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. *Cochrane Database Syst Rev* 2007;(2):CD004659.
115. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. *Lancet* 2007;369:1791–8.
116. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of pre-eclampsia and intrauterine growth restriction with aspirin started in early pregnancy. *Obstet Gynecol* 2010;116:402–14.
117. Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of pre-eclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. *J Obstet Gynecol Can* 2009;31:818–26.
118. Kramer MS, Kakuma R. Energy and protein intake in pregnancy. *Cochrane Database Syst Rev* 2010;(9): CD000032.
119. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. *Cochrane Database Syst Rev* 2006;(4):CD004905.
120. Say L, Gulmezoglu AM, Hofmeyer JG. *Maternal nutrient supplementation for suspected impaired fetal growth*. Cochrane Summaries;2010 [http://summaries.cochrane.org/CD000148/maternal-nutrient-supplementation-for-suspected-impaired-fetal-growth].
121. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy complicated by pre-eclampsia or intrauterine growth retardation. *Cochrane Database Syst Rev* 2006;(3):CD003402.
122. Meher S, Duley L. Progesterone for preventing pre-eclampsia and its complications. *Cochrane Database Syst Rev* 2006;(4):CD006175.
123. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev* 2010;(8):CD001059.
124. Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions to promote smoking cessation during pregnancy. *Cochrane Database Syst Rev* 2009;(3):CD001055.
125. Dodd JM, McLeod A, Windrim R, Kingdom J. Antithrombotic therapy for improving maternal and infant health outcomes in women considered at risk of placental dysfunction. *Cochrane Database Syst Rev* 2010;(6):CD006780.
126. Abalos E, Duley L, Steyn WD, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev* 2007;(1):CD002252.
127. Magee L, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev* 2003;(3):CD002863.
128. Nabhan AF, Elsedawy MM. Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension. *Cochrane Database Syst Rev* 2011;(7):CD006907.
129. Royal College of Obstetricians and Gynaecologists. *Antenatal Corticosteroids to Prevent Neonatal Morbidity and Mortality*. Green-top Guideline no. 7. London: RCOG; 2010.
130. Say L, Gulmezoglu MA, Hofmeyer JG. Bed rest in hospital for suspected impaired fetal growth. *Cochrane Database Syst Rev* 1996;(1):CD000034.
131. Say L, Gulmezoglu MA, Hofmeyer GJ. Maternal oxygen administration for suspected impaired fetal growth. *Cochrane Database Syst Rev* 2003;(1):CD000137.

132. Royal College of Obstetricians and Gynaecologists. *Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth. Scientific Impact Paper No. 29*. London;RCOG:2011.
133. Australian Research Centre for Health of Women and Babies. *Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child - National Clinical Practice Guidelines*. Adelaide;ARCH:2010.
134. Morris RK, Malin G, Robson SC, Kleijnen J, Zamora J, Khan KS. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in high-risk population: systematic review and bivariate meta-analysis. *Ultrasound Obstet Gynecol* 2011;37: 135-42.
135. Alfrevic Z, Stampalija T, Gyte GL. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. *Cochrane Database Syst Rev* 2010;(1):CD007529.pub2.
136. Soothill PW, Ajayi RA, Campbell S, Nicolaides KH. Prediction of morbidity in small and normally grown fetuses by fetal heart rate variability, biophysical profile score and umbilical artery Doppler studies. *BJOG* 1993;100:742-5.
137. Haley J, Tuffnell DJ, Johnson N. Randomised controlled trial of cardiotocography versus umbilical artery Doppler in the management of small for gestational age fetuses. *BJOG* 1997;104:431-5.
138. Almstrom H, Ekman G, Axelsson O, Ulmsten U, Cnattingius S, Maesel A, et al. Comparison of umbilical artery velocimetry and cardiotocography for surveillance of small-for-gestational-age fetuses. *Lancet* 1992;340:936-40.
139. Williams KP, Farquharson DF, Bebbington M, Dansereau J, Galerneau F, Wilson RD, et al. Screening for fetal wellbeing in a high risk pregnant population comparing the nonstress test with umbilical artery Doppler velocimetry: A randomized controlled clinical trial. *Am J Obstet Gynecol* 2003;188:1366-71.
140. Maulik D, Yarlagadda P, Youngblood JP, Ciston P. Comparative efficacy of umbilical arterial Doppler indices for predicting adverse perinatal outcome. *Am J Obstet Gynecol* 1991;164:1434-9.
141. Figueras F, Eixarch E, Gratacos E, Gardosi J. Predictiveness of antenatal umbilical artery Doppler for adverse pregnancy outcome in small-for-gestational age according to customised birthweight centiles: population-based study. *BJOG* 2008;115:590-94.
142. Nienhuis SJ, Vles JS, Gerver WJ, Hoogland HJ. Doppler ultrasonography in suspected intrauterine growth retardation: a randomized clinical trial. *Ultrasound Obstet Gynecol* 1997;9:6-13.
143. McCowan LM, Harding JE, Roberts AB, Barker SE, Ford C, Stewart AW. A pilot randomized controlled trial of two regimens of fetal surveillance for small-for-gestational-age fetuses with normal results of umbilical artery Doppler velocimetry. *Am J Obstet Gynecol* 2000;182:81-6.
144. Lindqvist PG, Molin J. Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? *Ultrasound Obstet Gynecol* 2005;25:258-64.
145. Figueras F, Eixarch E, Meler E, Iraola A, Figueras J, Puerto B, et al. Small-for-gestational-age fetuses with normal umbilical artery Doppler have suboptimal perinatal and neurodevelopmental outcome. *Eur J Obstet Gynecol Reprod Biol* 2008;136:34-8.
146. Alfrevic Z, Stampalija T, Gyte GLM. Fetal and umbilical artery Doppler ultrasound in normal pregnancy. *Cochrane Database of Syst Rev* 2010;(8):CD001450.
147. Grivell RM, Alfrevic Z, Gyte GML, Devane D. Antenatal cardiotocography for fetal assessment. *Cochrane Database Syst Rev* 2010;(1):CD007863.
148. Dawes GS, Moulden M, Redman CW. Improvements in computerised fetal heart rate pattern analysis antepartum. *J Perinat Med* 1996;24:25-36.
149. Serra V, Bellver J, Moulden M, Redman CW. Computerized analysis of normal fetal heart rate pattern throughout gestation. *Ultrasound Obstet Gynecol* 2009;34:74-9.
150. Turan S, Turan OM, Berg C, Moyano D, Bhide A, Bower S, et al. Computerized fetal heart rate analysis, Doppler ultrasound and biophysical profile score in the prediction of acid-base status of growth-restricted fetuses. *Ultrasound Obstet Gynecol* 2007;30:750-6.
151. Serra V, Moulden M, Bellver J, Redman CW. The value of the short-term fetal heart rate variation for timing the delivery of the growth-retarded fetuses. *BJOG* 2008;115:1101-7.
152. Magann EF, Isler CM, Chauhan SP, Martin JN. Amniotic fluid volume estimation and the biophysical profile. *Obstet Gynecol* 2000;96:640-2.
153. Nabhan AF, Abdelmoula YA. Amniotic fluid index versus single deepest vertical pocket as a screening test for preventing adverse pregnancy outcome. *Cochrane Database Syst Rev* 2008;(3):CD006593.
154. Zhang J, Troendle J, Meikle S, Klebanoff MA, Rayburn WF. Isolated oligohydramnios is not associated with adverse perinatal outcomes. *BJOG* 2004;111:220-5.
155. Chauhan SP, Sanderson M, Hendrix NW, Magann EF, Devoe LD. Perinatal outcome and amniotic fluid index in the antepartum and intrapartum periods: A meta-analysis. *Am J Obstet Gynecol* 1999;181:1473-8.
156. Bastide A, Manning F, Harman C, Lange I, Morrison I. Ultrasound evaluation of amniotic fluid: outcome of pregnancies with severe oligohydramnios. *Am J Obstet Gynecol* 1986;154:895-900.
157. Manning FA. Fetal biophysical profile: a critical appraisal. *Fetal Mat Med Rev* 1997;9:103-23.
158. Baschat AA, Galan HL, Bhide A, Berg C, Kush ML, Oepkes D, et al. Doppler and biophysical assessment in growth restricted fetuses: distribution of test results. *Ultrasound Obstet Gynecol* 2006;27:41-7.
159. Lalor JG, Fawole B, Alfrevic Z, Devane D. Biophysical profile for fetal assessment in high risk pregnancies. *Cochrane Database Syst Rev* 2008;(1):CD007529.
160. Dayal AK, Manning FA, Berck DJ, Mussalli GM, Avila C, Harman CR, et al. Fetal death after normal biophysical profile score: An eighteen-year experience. *Am J Obstet Gynecol* 1999;181:1231-6.
161. Kaur S, Picconi JL, Chadha R, Kruger M, Mari G. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh <1000g. *Am J Obstet Gynecol* 2008;199:1-4.
162. Rizzo G, Capponi A, Arduini D, Romanini C. The value of fetal arterial and venous flows in predicting pH and blood gases measured in umbilical blood at cordocentesis in growth restricted fetuses. *BJOG* 1995;102:963-9.
163. Arduini D, Rizzo G, Romanini C. Changes in pulsatility index from fetal vessels preceding the onset of late decelerations in growth retarded fetuses. *Obstet Gynecol* 1992;79:605-10.
164. Dubiel M, Gudmundsson S, Gunnarsson G, Marsal K. Middle cerebral artery velocimetry as a predictor of hypoxemia in fetuses with increased resistance to blood flow in the umbilical artery. *Early Hum Dev* 1997;47:177-84.
165. Morris RK, Say R, Robson SC, Kleijnen J, Khan KS. Systematic review of middle cerebral artery Doppler to predict fetal growth restriction/compromise of fetal wellbeing. *Arch Dis Child Fetal Neonatal Ed* 2008;93(Suppl 1):31-6.
166. Ozeren M, Dinc H, Ekmen U, Senekayli C, Aydemir V. Umbilical and middle cerebral artery Doppler indices in patients with pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol* 1999;82:11-6.
167. Vergani P, Roncaglia N, Ghidini A, Crippier I, Cameroni I, Orsenigo F, et al. Can adverse neonatal outcome be predicted in late preterm or term fetal growth restriction? *Ultrasound Obstet Gynecol* 2010;36:166-70.
168. Baschat AA, Cosmi E, Bilardo CM, Wolf H, Berg C, Rigano S, et al. Predictors of neonatal outcome in early-onset placental dysfunction. *Obstet Gynecol* 2007;109:253-61.
169. Fieni S, Gramellini D, Piantelli G. Lack of normalisation of middle cerebral artery velocity prior to fetal death before 30th week of gestation: a report of three cases. *Ultrasound Obstet Gynecol* 2004;24:474-5.

170. Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. *Ultrasound Obstet Gynecol* 2001;18:571-7.
171. Oros D, Figueras F, Cruz-Martinez R, Meler E, Munmany M, Gratecos E. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational-age fetuses. *Ultrasound Obstet Gynecol* 2011;37:191-5.
172. Hershkovitz R, Kingdom JC, Geary M, Rodeck CH. Fetal cerebral blood flow redistribution in late gestation: identification of compromise in small fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol* 2000;15:209-12.
173. Severi FM, Bocchi C, Visentin A, Falco P, Cobellis L, Florio P, et al. Uterine and fetal cerebral Doppler predict the outcome of third-trimester small-for-gestational age fetuses with normal umbilical artery Doppler. *Ultrasound Obstet Gynecol* 2002;19:225-8.
174. Cruz-Martinez R, Figueras F, Hernandez-Andrade E, Oros D, Gratecos E. Fetal brain Doppler to predict cesarean delivery for nonreassuring fetal status in term small-for-gestational-age fetuses. *Obstet Gynecol* 2011;117:618-26.
175. Yagel S, Kivilevitch Z, Cohen SM, Valsky DV, Messing B, Shen O, et al. The fetal venous system, Part II: ultrasound evaluation of the fetus with congenital venous system malformation or developing circulatory compromise. *Ultrasound Obstet Gynecol* 2010;36:93-111.
176. Morris RK, Selman TJ, Verma M, Robson SC, Kleijnen J, Khan KS. Systematic review and meta-analysis of the test accuracy of ductus venosus Doppler to predict compromise of fetal/neonatal wellbeing. *Eur J Obstet Gynecol Reprod Biol* 2010;152:3-12.
177. Baschat AA, Guclu S, Kush ML, Gembruch U, Weiner CP, Harman CR. Venous Doppler in the prediction of acid-base status of growth restricted fetuses with elevated placental blood flow resistance. *Am J Obstet Gynecol* 2004;191:277-84.
178. Baschat AA. Doppler application in the delivery timing of the preterm growth-restricted fetus; another step in the right direction. *Ultrasound Obstet Gynecol* 2004;23:111-8.
179. Cole TJ, Hey E, Richmond S. The PREM score: a graphical tool for predicting survival in very preterm births. *Arch Dis Fetal Neonat Ed* 2010;95:14-9.
180. Baschat AA. Neurodevelopment following fetal growth restriction and its relationship with antepartum parameters of placental dysfunction. *Ultrasound Obstet Gynecol* 2011;37:501-14.
181. Ferrazzi E, Bozzo M, Rigano S, Bellotti M, Morabito A, Pardi G, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. *Ultrasound Obstet Gynecol* 2002;19:140-6.
182. Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackelöer BJ, Kok HJ, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. *Ultrasound Obstet Gynecol* 2002;18:565-70.
183. GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. *BJOG* 2003;110:27-32.
184. Thornton JG, Hornbuckle J, Vail A, Spiegelhalter DJ, Levene M; GRIT study group. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. *Lancet* 2004;364:513-20.
185. Wilkinson AR, Ahluwalia J, Cole A, Crawford D, Fyle J, Gordon A, et al. Management of babies born extremely preterm at less than 26 weeks of gestation: a framework for clinical practice at the time of birth. *Arch Dis Child Fetal Neonatal Ed* 2009;94:2-5.
186. Lees C. Protocol 02PRT/34 Trial of umbilical and fetal flow in Europe (TRUFFLE): a multicentre randomised study. [<http://www.thelancet.com/journals/lancet/misc/protocol/02PRT-34>].
187. Boers KE, Vijgen SM, Bijlenga D, van der Post JA, Bekedam DJ, Kwee A, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). *BMJ* 2010;341.
188. Nicolaides KH, Economides DL, Soothill PW. Blood gases, pH and lactate in appropriate and small for gestational age fetuses. *Am J Obstet Gynecol* 1989;161:996-1001.
189. Robson SC, Crawford RA, Spencer JA, Lee A. Intrapartum amniotic fluid and its relationship to fetal distress. *Am J Obstet Gynecol* 1992;166:78-82.
190. Lin CC, Moawad AH, Rosenow PJ, River P. Acid-base characteristics of fetuses with intrauterine growth retardation during labour and delivery. *Am J Obstet Gynecol* 1980;137:553-9.
191. Burke G, Stuart B, Crowley P, Ni Scanail S, Drumm J. Is intrauterine growth retardation with normal umbilical artery blood flow a benign condition? *BMJ* 1990;300:1044-5.
192. Baschat AA, Weiner CP. Umbilical artery Doppler screening for detection of the small fetus in need of antepartum surveillance. *Am J Obstet Gynecol* 2000;182:154-8.
193. Karsdrop VH, van Vugt JM, van Geijn HP, Kostense PJ, Arduin D, Montenegro N, et al. Clinical significance of absent or reversed end diastolic waveforms in umbilical artery. *Lancet* 1994;344:1664-8.
194. Forouzan I. Absence of End-Diastolic Flow Velocity in the Umbilical Artery: A Review. *Obstet Gynecol Survey* 1995;50:219-27.
195. Li H, Gudmundsson S, Olofsson P. Prospect of vaginal delivery of growth restricted fetuses with abnormal umbilical artery blood flow. *Acta Obstet Gynecol Scand* 2003;82:828-33.
196. Almström H, Axelsson O, Ekman G, Ingemarsson I, Maesel A, Arström K, et al. Umbilical artery velocimetry may influence clinical interpretation of intrapartum cardiotocograms. *Acta Obstet Gynecol Scand* 1995;74:526-9.
197. National Institute for Health and Clinical Excellence (NICE). *Induction of labour*. London; NICE:2008.

## Appendix I: Summary of Risk Factors for a Small-for-Gestational-Age Neonate.

**Table A:** Available from history at booking (usually prior to 12 weeks)

Risk category	Definition of risk	Definition of outcome measure	Estimate measure	Point estimate and 95% CI
<b>Maternal Risk Factors</b>				
Age	Maternal age $\geq$ 35 years <sup>22</sup>	BW < 10th centile population	OR	1.4 (1.1–1.8)
	<b>Maternal age &gt; 40 years<sup>22†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>OR</b>	<b>3.2 (1.9–5.4)</b>
Parity	Nulliparity <sup>25</sup>	BW < 10th centile population*	OR	1.89 (1.82–1.96)
BMI	BMI < 20 <sup>28</sup>	BW < 10th centile customised	OR	1.2 (1.1–1.3)
	BMI 25–29.9 <sup>28</sup>	BW < 10th centile customised	RR	1.2 (1.1–1.3)
	BMI $\geq$ 30 <sup>28</sup>	BW < 10th centile customised	RR	1.5 (1.3–1.7)
Maternal substance Exposure	Smoker <sup>32</sup>	BW < 10th centile customised	AOR	1.4 (1.2–1.7)
	Smoker 1–10 cigarettes per day <sup>29</sup>	BW < 9.9th centile population	OR	1.54 (1.39–1.7)
	<b>Smoker <math>\geq</math> 11 cigarettes per day<sup>29†</sup></b>	<b>BW &lt; 9.9th centile population</b>	<b>OR</b>	<b>2.21 (2.03–2.4)</b>
	<b>Cocaine<sup>38†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>OR</b>	<b>3.23 (2.43–4.3)</b>
IVF	IVF singleton pregnancy <sup>41</sup>	BW < 10th centile	OR	1.6 (1.3–2.0)
Exercise	<b>Daily vigorous exercise<sup>32†</sup></b>	<b>BW &lt; 10th centile customised</b>	<b>AOR</b>	<b>3.3 (1.5–7.2)</b>
Diet	Low fruit intake pre-pregnancy <sup>32◊</sup>	BW < 10th centile customised	AOR	1.9 (1.3–2.8)
<b>Previous Pregnancy History</b>				
Previous SGA	<b>Previous SGA baby<sup>8†</sup></b>	<b>BW &lt; 10th centile customised</b>	<b>OR</b>	<b>3.9 (2.14–7.12)</b>
Previous Stillbirth	<b>Previous stillbirth<sup>8†</sup></b>	<b>BW &lt; 10th centile customised</b>	<b>OR</b>	<b>6.4 (0.78–52.56)</b>
Previous pre-eclampsia	Pre-eclampsia <sup>9</sup>	BW < 10th centile population	AOR	1.31 (1.19–1.44)
Pregnancy Interval	Pregnancy interval < 6 months <sup>33</sup>	SGA not defined*	AOR	1.26 (1.18–1.33)
	Pregnancy interval $\geq$ 60 months <sup>33</sup>	SGA not defined*	AOR	1.29 (1.2–1.39)
<b>Maternal Medical History</b>				
SGA◊	<b>Maternal SGA<sup>31†</sup></b>	<b>BW &lt; 10th centile population*</b>	<b>OR</b>	<b>2.64 (2.28–3.05)</b>
Hypertension	<b>Chronic hypertension<sup>17†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>ARR</b>	<b>2.5 (2.1–2.9)</b>
Diabetes	<b>Diabetes with vascular disease<sup>14†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>OR</b>	<b>6 (1.5–2.3)</b>
Renal disease	<b>Renal impairment<sup>15†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>AOR</b>	<b>5.3 (2.8–10)</b>
APLS	<b>Antiphospholipid syndrome<sup>16†</sup></b>	<b>FGR no definition</b>	<b>RR</b>	<b>6.22 (2.43–16.0)</b>
<b>Paternal Medical History◊</b>				
SGA	<b>Paternal SGA<sup>43†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>OR</b>	<b>3.47 (1.17–10.27)</b>

**Table B:** Current pregnancy complications/developments


Risk category	Definition of risk	Definition of outcome measure	Estimate measure	Point estimate and 95% CI
Threatened miscarriage	<b>Heavy bleeding similar to menses<sup>34†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>AOR</b>	<b>2.6 (1.2–5.6)</b>
Ultrasound appearance	<b>Echogenic bowel<sup>62†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>AOR</b>	<b>2.1 (1.5–2.9)</b>
Pre-eclampsia	<b>Pre-eclampsia<sup>8†</sup></b>	<b>BW &lt; 10th centile customised</b>	<b>AOR</b>	<b>2.26 (1.22–4.18)</b>
Pregnancy induced hypertension	Mild <sup>17</sup>	BW < 10th centile population	RR	1.3 (1.3–1.4)
	<b>Severe<sup>17†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>RR</b>	<b>2.5 (2.3–2.8)</b>
Placental abruption	Placental abruption <sup>61</sup>	SGA not defined*	OR range	1.3–4.1
Unexplained APH	<b>Unexplained APH<sup>44†</sup></b>	<b>'UGR' not defined</b>	<b>OR</b>	<b>5.6 (2.5–12.2)</b>
Weight gain◊	<b>Low maternal weight gain<sup>13†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>OR</b>	<b>4.9 (1.9–12.6)</b>
Exposure◊	Caffeine $\geq$ 300 mg/day in third trimester <sup>40</sup>	BW < 10th centile population	OR	1.9 (1.3–2.8)
DS marker	<b>PAPP-A &lt; 0.4 MoM<sup>45†</sup></b>	<b>BW &lt; 10th centile population</b>	<b>OR</b>	<b>2.6</b>

\* Denotes data from systematic review


◊ Information regarding these risk factors may be unobtainable

† Major risk factors are in bold

## APPENDIX II: Screening for Small-for-Gestational-Age (SGA) Fetus



### APPENDIX III: The Management of the Small-for-Gestational-Age (SGA) Fetus



<sup>1</sup> Weekly measurement of fetal size is valuable in predicting birthweight and determining size-for-gestational age

<sup>2</sup> If two AC/EFW measurements are used to estimate growth, they should be at least 3 weeks apart

<sup>3</sup> Use cCTG when DV Doppler is unavailable or results are inconsistent – recommend delivery if STV < 3 ms

**Abbreviations:** AC, abdominal circumference; EFW, estimated fetal weight; PI, pulsatility index; RI, resistance index; UA, umbilical artery; MCA, middle cerebral artery; DV, ducts venosus; SD, standard deviation; AREDV, Absent/reversed end-diastolic velocities; cCTG, computerised cardiotography; STV, short term variation; SFH, symphysis–fundal height; FGR, fetal growth restriction; EDV, end-diastolic velocities.

## APPENDIX IV: Glossary


AC	Abdominal circumference
AFI	Amniotic fluid index
AFP	Alpha fetoprotein
AGA	Appropriate for gestational age
AOR	Adjusted odds ratio
APH	Antepartum haemorrhage
AREDV	Absent or Reversed End-Diastolic Velocity
BMI	Body mass index
BPP	Biophysical profile
CI	Confidence interval
CTG	Cardiotocography
cCTG	Computerised cardiotocography
CMV	Cytomegalo virus
DS	Down Syndrome
DV	Ductus venosus
EDV	End-diastolic velocities
EFW	Estimated fetal weight
FGR	Fetal growth restriction
FHR	Fetal heart rate
GRIT	Growth restriction intervention trial
hCG	Human chorionic gonadotrophin
IPD	Individual patient data
LBW	Low birth weight
LR	Likelihood ratio
LR+	Positive likelihood ratio
LR-	Negative likelihood ratio
MCA	Middle cerebral artery
MeSH	Medical subject heading
MoM	Multiples of the median
OR	Odds ratio
PAPP-A	Pregnancy associated plasma protein-A
PI	Pulsatility Index
PIV	Pulsatility Index for veins
PREM	Prematurity risk evaluation measure
RCT	Randomised controlled trial
RR	Relative risk
SDVP	Single deepest vertical pocket
SFH	Symphysis fundal height
SGA	Small-for-gestational-age
STV	Short term variation
TRUFFLE	Trial of umbilical and fetal flow in Europe



## APPENDIX V: Explanation of Guidelines and Evidence Levels

Clinical guidelines are: 'systematically developed statements which assist clinicians and women in making decisions about appropriate treatment for specific conditions'. Each guideline is systematically developed using a standardised methodology. Exact details of this process can be found in Clinical Governance Advice No.1: *Development of RCOG Green-top Guidelines* (available on the RCOG website at <http://www.rcog.org.uk/green-top-development>). These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research might be indicated.

The evidence used in this guideline was graded using the scheme below and the recommendations formulated in a similar fashion with a standardised grading scheme.

Classification of evidence levels	Grades of recommendations
1++ High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias	<b>A</b> At least one meta-analysis, systematic review or randomised controlled trial rated as 1++ and directly applicable to the target population; or A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results
1+ Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias	<b>B</b> A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
1- Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias	<b>C</b> A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++
2++ High-quality systematic reviews of case-control or cohort studies or high-quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal	<b>D</b> Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+
2+ Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal	<b>Good practice point</b>  Recommended best practice based on the clinical experience of the guideline development group
2- Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal	
3 Non-analytical studies, e.g. case reports, case series	
4 Expert opinion	

This guideline was produced on behalf of the Guidelines Committee of the Royal College of Obstetricians and Gynaecologists by:

**Professor SC Robson MRCOG, Newcastle-upon-Tyne; Dr WL Martin FRCOG, Birmingham and Dr RK Morris MRCOG, Birmingham.**

Committee Lead Reviewers: Dr P Owen FRCOG, Glasgow, Scotland; Ms CJ Elson FRCOG, Leicestershire; Mr DJ Cruickshank FRCOG, Middlesbrough

and peer-reviewed by: British Maternal and Fetal Medicine Society (BMFMS); British Medical Ultrasound Society (BMUS); British Society of Urogenital Radiology (BSUR); Clinical Studies Group for Stillbirth (CSGS, hosted by SANDS); International Society of Ultrasound in Obstetrics and Gynaecologist (ISUOG); Perinatal Institute; Dr UB Agarwal MRCOG, Liverpool; Professor JC Dornan FRCOG, County Down, Northern Ireland; Dr MA Harper FRCOG, Belfast; Mr B Kumar FRCOG, Wrexham; Dr AC McKelvey MRCOG, Norfolk; Professor LME McCowan, University of Auckland, New Zealand; Mr DJ Tuffnell FRCOG, Bradford; Mr SA Walkinshaw FRCOG, Liverpool.

Conflicts of interest; none declared.

The final version is the responsibility of the Guidelines Committee of the RCOG

The review process will commence in 2016, unless otherwise indicated.

#### DISCLAIMER

The Royal College of Obstetricians and Gynaecologists produces guidelines as an educational aid to good clinical practice. They present recognised methods and techniques of clinical practice, based on published evidence, for consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical data presented by the patient and the diagnostic and treatment options available within the appropriate health services.

This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or guidelines should be fully documented in the patient's case notes at the time the relevant decision is taken.